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Abstract 
 
The nuclear factor-kappa B (NF-κB) family of transcription factors play a pivotal role in 
the inflammatory and immune responses, as well as cell growth and survival. Since its discovery 
25 years ago, NF-κB has emerged as one of the most intensely studied eukaryotic transcription 
factors, due to its pleiotropic functions and its inducible pattern of expression that is subject to 
multi-level regulation. Many modulatory events affect NF-kB function and thus to have a better 
understanding of the NF-κB pathway and its gene regulation will require additional studies of 
NF-κB’s modulators.  
The goal of this thesis was to investigate the role of intra- and extra-cellular modulators 
of NF-κB. To study how intracellular modulators affect NF-κB function, various genetic and 
biochemical approaches were used to identify potentially new NF-κB’s interacting proteins. Two 
AGC family kinases, STK38 and STK38L, were chosen for further study. These two proteins 
were found to not only interact with NF-κB’s p65 subunit but also act as its kinases in vitro. 
shRNA mediated knockdown combined with gene expression analysis revealed that STK38 and 
STK38L via their kinase function regulated p65 activity on some, but not all NF-κB-responsive 
inflammatory genes in response to TNFα stimulation. To study the role of extracellular 
modulators on the apoptotic behaviors of cells, a panel of human immortalized and cancer liver 
cell lines were pre-treated with pro-inflammatory cytokines TNFα and IL-1α followed by 
TRAIL, a potent inducer of cell death. This context-dependent approach revealed that TNFα and 
IL-1α had diverse effects on cell death behaviors and inhibiting the NF-κB pathway was enough 
to block pro-inflammatory cytokines-mediated pro-death or pro-survival outcomes. Chromatin 
immunoprecipitation followed by high throughput sequencing, realtime PCR and Western 
blotting were used to identify NF-κB’s target genes involved in the cell death pathway. From 
these data, new regulatory mechanisms that affect cell death behaviors were proposed. 
Dysregulation of NF-κB activation has been implicated in various pathologies including 
inflammatory diseases and cancer. The results described here represent progress toward 
understanding the NF-κB pathway and its gene regulation program. The more we understand this 
pathway, the better we are at targeting it for disease treatments.  
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Discovered 25 years ago, the transcription factor nuclear factor-kappa B, also known as 
NF-κB is still one of the most studied proteins due to its pleiotropic functions and its 
involvement in inflammatory diseases and cancer (Ghosh and Hayden, 2008; Ghosh et al., 1998; 
Karin, 2009; Sen and Baltimore, 1986; Vallabhapurapu and Karin, 2009). NF-κB directly 
regulates a wide range of genes that control the inflammatory and immune responses, 
programmed cell death, cell proliferation and differentiation (Chen and Greene, 2004). The 
important role played by NF-κB proteins is illustrated not only by the diversity of genes that they 
regulate, but also by the large variety of stimuli that lead to their activation (Wan and Lenardo, 
2010).  
The Rel/NF-κB transcription factor family is comprised of several structurally-related 
proteins that exist in organisms from insects to humans (Barkett and Gilmore, 1999; Gonzalez-
Crespo and Levine, 1994). The vertebrate family is expressed by five known NF-κB/REL genes, 
RELA, c-REL, RELB, NFΚB1, and NFΚB2 that give rise to seven protein products:  RELA 
(p65), c-REL, RELB, p105/p50, and p100/p52 (p50 and p52 are the cleaved forms of p105 and 
p100, respectively). In cells, NF-κB proteins interact to form homo- and heterodimers, the most 
abundant of which is a p65/p50 heterodimer containing RELA and the cleaved form of the 
NFKB1 gene product. Dimerization is mediated by an N-terminal REL-homology domain 
(RHD) of ~300 amino acids that is present in all NF-κB proteins and is also responsible for 
binding to DNA and to the IκB family of NF-κB inhibitors (Hoffmann and Baltimore, 2006).  
All IκB proteins have a core domain, which consists of multiple ankryin repeats necessary for 
interactions with Rel proteins. The best-studied IκB protein is IκBα. The C-terminus of the pre-
processed form of p105 and p100 also contains ankryin repeats, and thus can act to inhibit NF-
κB  in a similar manner like IκBs (Chen and Ghosh, 1999). 
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Activation of NF-κB is tightly controlled both in the cytoplasm and in the nucleus. While 
the early cytoplasmic events that lead to nuclear translocation of NF-κB have been studied in 
considerable detail, current understanding of NF-κB regulation does not fully explain its 
temporal, ligand or cell-type specificity. Emerging evidence suggests that posttranslational 
modification and recruitment of cofactors play a key role in determining the duration and 
strength of NF-κB nuclear activity as well as its gene expression program (Natoli and De Santa, 
2006). Thus, to gain a better insight into the molecular mechanisms that mediate cell type- and 
stimulus-specific functions of this pleiotropic signaling system will require additional studies of 
the intra- and extra-cellular modulators of NF-κB.  
 
1.1   Specific aims 
 In this thesis, I set out to investigate the role of intra- and extra-cellular modulators of 
NF-κB. The first aim examines the role of intracellular modulators of NF-κB. I first generated a 
knock-in cell line carrying an affinity purification tag. Then, using affinity purification followed 
by mass spectrometry, potentially new NF-κB’s interacting proteins were identified. Two p65’s 
binding protein STK38 and STK38L were selected for further study. Since these two proteins 
belong to the AGC kinase family (Hergovich et al., 2008), in vitro kinase assay was carried out 
to determine whether p65 is a substrate. Next, phospho-mass spectrometry was used to identify 
the phosphorylation sites. To study how STK38 and STK38 affect p65 function, an shRNA 
double knockdown cell line of STK38 and STK38L was generated. Gene expression microarray 
was performed to find NF-κB -dependent genes that were also coregulated by STK38 and 
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STK38L. Chromatin immunoprecipitation was performed to study how STK38 and STK38L 
affect p65 binding to certain gene promoters.   
 The second aim explores the role of extracellular modulators of NF-κB. A panel of 
immortalized and cancer liver cell lines were stimulated with pro-inflammatory cytokine TNFα 
or IL-1α for various amounts of time. To investigate how pretreatments of cells with TNFα or 
IL-1α affect their apoptotic responses, TRAIL was added to induce cell death following pro-
inflammatory cytokine treatments. TNFα and IL-1α were observed to induce diverse apoptotic 
outcomes. To examine whether NF-κB is responsible for such outcomes, an NF-κB dominant 
negative inhibitor was introduced into cells. To identify genes activated by NF-κB in response to 
pro-inflammatory cytokine treatment, a chromatin immunoprecipitation followed by high 
throughput sequencing experiment was carried out followed by realtime PCR and Western 
blotting. This type of context-dependent approach allowed different NF-κB gene regulation 
programs to be examined, which can lead to identification of new regulatory mechanisms.    
 
1.2   The canonical pathway 
This pathway is activated by inflammatory cytokines such as TNFα and IL-1α, by 
engagement of T-cell receptor or by exposure to bacterial products such as LPS (Vallabhapurapu 
and Karin, 2009) (Figure 1.1A). The NF-κB dimers involved in this pathway are p65-p50 and c-
Rel-p50 with the p65-p50 dimer being the most studied.  In unstimulated cells, NF-κB proteins 
are sequestered in the cytoplasm due to their association with a family of inhibitor proteins called 
IκBs with IκBα and IκBβ being the most relevant (Baldwin, 1996; Verma et al., 1995). Upon 
ligand binding and activation of receptors, different types of adaptor molecules are recruited to 
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the receptors’ intracellular domains (details on the adaptor’s recruitment will be discussed in 
later sections), which results in the activation of an IκB kinase complex IKK (Li et al., 1999). 
This kinase when activated phosphorylates IκBα on two serine residues, S32 and S36, and thus 
marking this inhibitor for further modifications by ubiquitin enzymes and eventually degradation 
by the 26S proteosome. Once IκB is removed, NF-κB can freely translocate into the nucleus 
where it binds to gene promoters and regulate their expression.   
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Figure 1.1 Activation of the NF-κB pathway (A)The canonical pathway is activated by 
inflammatory cytokines such as TNF-α and IL-1α or bacterial lipopolysacharide (LPS) or viral 
protein TAX. In unstimulated cells, NF-κB, primarily the RelA (p65)-p50 heterodimer, is 
sequestered in the cytoplasm by an NF-κB inhibitor protein IκB. Ligand binding leads to 
recruitment of adaptor proteins to the intracellular domain of receptors and activation of a kinase 
complex, IKK. IKK2 (IKK-β) of actiavted IKK phosphorylates IκBα and marks this inhibitor 
protein for proteosomal degradation. Degradation of IκBα frees NF-κB and allows it to enter the 
nucleus to activate gene transcription. (B) The alternative pathway is actiavted by stimuli 
including CD40 ligand (CD40L), lymphotoxin beta (LT-β), B cell–activating factor (BAFF). In 
unstimulated cells, NF-κB, primarily the RelB-p100 heterodimer, is sequestered in the 
cytoplasm. Ligand binding leads to recruitment of adaptor proteins to the intracellular domain of 
receptors and activation of the IKK1 upstream kinase called NIK. Activated IKK1 (IKK-α) 
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phosphorylates p100 and results in its partial degradation. The new NF-κB dimer of RelB and 
p52 (the partially degraded product of p100) translocates into the nucleus and activates gene 
transcription. Adapted from Chen and Greene, 2004. 
 
 
1.3   The alternative pathway 
 This pathway is activated in response to a small subset of TNF family members, 
including CD40L (CD40 ligand), LTβ (lymphotoxin beta), BAFF (B cell–activating factor), 
RANKL (receptor activator of NF-κB ligand), and TWEAK (TNF-related weak inducer of 
apoptosis) (Claudio et al., 2002; Coope et al., 2002; Saitoh et al., 2003; Yilmaz et al., 2003) 
(Figure 1.1B). The main NF-κB dimer involved in this pathway is the p100-RelB heterodimer. 
Similar to the canonical pathway, in resting conditions this dimer is kept in the cytoplasm with 
the C terminus of p100 functioning like an IκB protein. An extracellular stimulation then leads to 
activation of a kinase called NIK (NF-κB inducing kinase), which is an upstream kinase of IKKα 
(Senftleben et al., 2001; Xiao et al., 2001). Activated IKKα phosphorylates the C terminus of 
p100, resulting in its partial degradation and the remaining protein p52 together with the bound 
RelB is liberated and can translocate into the nucleus and activate a gene transcription program.    
 
1.4   Extracellular modulators of NF-κB  
 NF-κB  has been shown to be activated by a variety of extracellular signals via several 
main groups of receptors including the TNF receptors family, the pattern-recognition Toll like 
receptors (TLR), the IL-1 receptors and the antigen receptors (Vallabhapurapu and Karin, 2009). 
These receptors can potentially activate not only different members of the NF-κB  family but 
also other intracellular signaling and enzymatic proteins, which together results in the induction 
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of a unique gene transcription program. In the following sections, key and important molecules 
in each receptor-mediated NF-κB activation pathway will be described.   
1.4.1  The TNFR pathway 
 TNFα is the prototypic member of a large family of trimeric cytokines and is one of the 
most potent activators of NF-κB. TNFα binds to two receptors TNFR1 and TNFR2. TNFR1 is 
present on most cell types and plays a much broader role in NF-κB activation (Chen and 
Goeddel, 2002). Upon ligand binding, TNFR1 forms a homotrimer complex which induces the 
recruitment of adapter proteins including TNFR1-associated death domain protein (TRADD), 
TNFR-associated factor 2 and 5 (TRAF2/5) and receptor interacting protein 1 (RIP1) to its 
cytoplasmic domain (Hsu et al., 1996; Micheau and Tschopp, 2003) (Figure 1.2). TRAF2 then 
recruits IKK to the receptor and also causes K63-linked ubiquitination of  RIP1 (Ea et al., 2006; 
Meylan et al., 2004).  Binding of IKKγ (NEMO) to ubiquitinated RIP1 stabilizes IKK interaction 
with the receptor complex, which facilitates its activation by either TGF-beta activated kinase 1 
(TAK1) or MAPK kinase kinases 3 (MEKK3) (Blonska et al., 2004; Wang et al., 2001). 
Activated IKK phosphorylates IκBα at serine 32 and 36, resulting in its degradation by the 
proteosome. Degradation of IκBα frees the NF-κB p65-p50 heterodimer, allows it to migrate to 
the nucleus and regulate gene expression. 
 
17 
 
 
Figure 1.2  The TNFR pathway. Ligation of TNFR results in TRADD-dependent 
TRAF2/TRAF5 and RIP1 recruitment. TRAF2 causes K63-linked ubiquitination of RIP1 and 
also recruits IKK to the receptor complex. TAB2 and TAB3 interact with TRAF2 and TAK1, 
leading to TAK1 activation and phosphorylation of IKKβ. Alternatively, MEKK3, which is 
brought near the receptor complex presumably by RIP1 can also phosphorylate and activate IKK. 
Activated IKK phosphorylates IκBα at specific serine residues, leading to its proteasome-
mediated degradation. Degradation of IκBα releases the NF-κB heterodimers and allows it to 
translocate into the nucleus and regulate gene expression. Adapted from Vallabhapurapu and 
Karin, 2009. 
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1.4.2  The TLR/IL-1 pathway 
 Members of the TLR/IL-1R family are potent inducers of the NF-κB canonical pathway. 
The cytoplasmic regions of TLR/IL-1R family proteins share a common motif called the 
Toll/Interleukin-1 receptor (TIR) domain (Kawai and Akira, 2007). Similar to TNFRs, ligation 
of TIR-containing receptors leads to recruitment of adapter proteins, ubiquitin ligases, and 
kinases to generate and transduce signals. Two adapter proteins, myeloid differentiation primary 
response gene 88 (MyD88) and TIR domain– containing adapter-inducing IFN-β (TRIF), play 
important roles in TLR/IL-1R signaling (Martin and Wesche, 2002). MyD88 recruits TRAF6 and 
IL-1R-associated kinase 1 (IRAK1), leading to self-ubiquitination of TRAF6 and recruitment of 
TAK1 binding protein 2/3 (TAB2/3), which in turn activate TAK1, an upstream kinase of IKKβ 
(Cao et al., 1996; Ishitani et al., 2003; Qian et al., 2001). Activated IKK causes phosphorylation 
and degradation of IκBα, resulting in NF-κB activation. Similar to MyD88, TRIF also recruits 
TRAF6, in addition to RIP1. TRAF6 and RIP1 together activate TAK1, culminating in IKK and 
NF-κB activation. In the case of TLR4 receptor, MyD88 and TRIF are recruited to these 
receptors via two bridging proteins TIR-adaptor protein (TIRAP for MyD88) and TRIF-related 
adaptor molecule (TRAM for TRIF) (Dunne et al., 2003; Yamamoto et al., 2003) (Figure 1.3). 
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Figure 1.3  The TLR/IL-1 pathway. Ligand binding by TLRs results in the recruitment of 
receptor-specific adapters and induces activation of NF-κB. In the case of TLR4, LPS binding 
results in NF-κB activation via both TRIF- and MyD88-dependent pathways. TIRAP and TRAM  
serve as bridging factors to recruit MyD88 and TRIF, respectively. MyD88 recruits TRAF6 and 
members of the IRAK family, leading to oligomerization and self-ubiquitination of TRAF6 as 
well as recruitment of TAB2 and TAB3, which in turn activate TAK1. Activated TAK1 
phosphorylates IKKβ, resulting in IκBα degradation and NF-κB activation. TRIF also recruits 
TRAF6. TRAF6 then activates TAK1, culminating in IKK and NF-κB activation in a manner 
similar to the MyD88-dependent pathway. In addition to recruiting TRAF6, TRIF also recruits 
RIP1, which might cooperate with TRAF6 to facilitate TAK1 activation. Adapted from 
Vallabhapurapu and Karin, 2009. 
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1.4.3  The TCR/BCR pathway 
 Stimulation of the T-cell and B-cell receptor (TCR/BCR) also results in IKK activation. 
The protein kinase C, PKCθ in T cells and PKCβ in B cells, plays a central role in recruiting 
intracellular signaling and adapter molecules to form spatially and temporally organized 
structures called supra-molecular activation clusters (SMACs) (Schulze-Luehrmann and Ghosh, 
2006; Su et al., 2002; Sun et al., 2000). In TCR signaling, these SMACs include caspase 
recruitment domain membrane associated guanylate kinase protein1(CARMA1),  B-cell 
lymphoma/leukemia 10 (BCL10), and mucosa-associated lymphoid tissue 1 (MALT1) (Weil and 
Israel, 2004) (Figure 1.4). The complex containing CARMA1, BCL10 and MALT1 facilitates 
the K63- polyubiquitination of IKKγ (NEMO), which results in activation of IKK and NF-κB. 
(Zhou et al., 2004).  
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Figure 1.4  The TCR pathway. Stimulation of a TCR results in recruitment and activation of 
the Src (Lck) and Syk (Zap) family kinases. Zap phosphorylates adapter proteins LAT and SLP-
76, leading to formation of a multimolecular complex containing PLCγ. Activation of PLCγ 
results in generation of IP3 and Ca2+, as well as DAG, which in turn stimulates PKCθ. Signals 
from TCR and CD28 costimulation result in activation of PI3K, which facilitates recruitment of 
PKCθ to the membrane. Phosphorylation of the phosphoinositides by PI3K leads to membrane 
recruitment of PDK1, which phosphorylates and activates PKCθ to control the recruitment of 
IKK and CARMA1 into the signaling complex. Phosphorylation of CARMA1 by PKCθ results 
in the recruitment of BCL10 and MALT1, leading to formation of a stable CBM complex. A 
poorly defined mechanism involving ubiquitination of IKKγ and activation of IKKβ presumably 
by TAK1 then leads to activation of IKK complex, which phosphorylates IκBα, resulting in its 
degradation and activation of NF-κB. Adapted from Vallabhapurapu and Karin, 2009. 
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1.5   Intracellular modulators of NF-κB  
 NF-κB is known to regulate hundreds of genes involved in many important cellular 
responses such as inflammation, migration, proliferation and apoptosis (Chen and Greene, 2004). 
So the obvious question is how a single transcription factor family can regulate so many different 
genes. Apparently, the early cytoplamsic events leading to the release and translocation of NF-
κB into the nucleus are not sufficient to explain the complex nature of NF-κB biology. In the last 
decade or so, it has become clear that additional events including posttranslational modifications 
and recruitment of cofactors play important roles in the NF-κB-dependent gene regulation 
(Huang et al., 2010; Wan and Lenardo, 2010). In the following sections, known NF-κB’s 
posttranslational modifications and coregulators will be described.  
1.5.1  Posttranslational modifications 
 Emerging evidence suggests that like other pleiotropic transcription factors such as p53, 
NF-κB is also subject to a variety of posttranslational modifications and that these modifications 
affect the duration and strength of NF-κB activation as well as its transcriptional output. Most of 
the known posttranslational modifications including phosphorylation, acetylation and 
methylation are associated with the NF-κB’s p65 subunit (Huang et al., 2010). The following 
sections will thus focus on describing posttranslational modifications of p65. 
1.5.1.1  Phosphorylation 
 Like kinases, phosphorylation of a transcription factor provides a powerful mechanism 
for the rapid and reversible integration of intracellular signals that ultimately results in activation 
of gene expression (Hunter, 2000). p65 has been shown to be phosphorylated by many kinases at 
multiple residues including seven serines and three threonines (Chen and Greene, 2004) (Figure 
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1.5A). Phosphorylation of p65 can occur both in the cytoplasm and in the nucleus. Depending on 
the site of phosphorylation, the target gene, and the stimulus, phosphorylation can cause an 
increase or decrease in the level of transcription. 
 Phosphorylation of serine 276 was first identified to be mediated by the catalytic subunit 
of the protein kinase A (PKAc) in response to lipopolysaccharide (LPS) (Zhong et al., 1997). 
Other ligands including TNF-α- and TGF-β were later found to also be able to activate PKAc 
and induce PKAc-mediated phosphorylation of S276 (Ishinaga et al., 2007; Jamaluddin et al., 
2007). Phosphorylation of S276 is believed to cause a conformational change in p65, which 
facilitates its binding to coregulators such as p300/CBP, leading to the overall increase in the 
transcriptional activity of NF-κB. S276 can be phosphorylated  by other kinases including the 
mitogen- and stress-activated protein kinase-1 (MSK1) in response to TNF-α, IL-1β, respiratory 
syncytial virus (RSV) and Helicobacter pylori infection (Pathak et al., 2006; Reber et al., 2009; 
Vermeulen et al., 2003). While PKAc phosphorylates p65 in the cytoplasm, MSK1, on the other 
hand, phosphorylates p65 in the nucleus. 
 Another well-studied phosphorylation site of p65 is serine 536. This site can be modified 
by different kinases including IKKs, ribosomal subunit kinase-1 (RSK1), and TANK binding 
kinase (TBK1) under various conditions with different functional outcomes (Adli and Baldwin, 
2006; Bohuslav et al., 2004; Buss et al., 2004b; Sakurai et al., 1999). The IKKs-mediated 
phosphorylation of S536 occurs in response to TNF-α, LPS, H. pylori and human T-
lymphotrophic virus-1 (HTLV1)-encoded TAX protein. Phosphorylation of S536 was also 
shown to enhance the transcriptional activity of NF-κB either by increasing p65's binding with 
p300 and decreasing its binding with co-repressor SMRT (as in the case of IKK) or by lowering 
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p65's affinity for IκBα and decreasing IκBα-mediated nuclear export of NF-κB (as in the case of 
RSK1 and TBK1).  
 NF-κB’s p65 can also be phosphorylated on serine 468. Interestingly, phosphorylation of 
S468 has different transcriptional outcomes depending on the cellular context. S468 is 
constitutively phosphorylated by GSK3β and this phosphorylation negatively affects the basal 
NF-κB activity (Buss et al., 2004a). In response to TNF-α and IL-1β, S468 is phosphorylated by 
IKKβ or IKKε, and phosphorylation of S468 by these kinases moderately reduces NF-κB activity 
via ubiquitin-mediated degradation of p65 (Geng et al., 2009; Mao et al., 2009; Schwabe and 
Sakurai, 2005). On the other hand, in response to T cell co-stimulation, IKKε was shown to 
phosphorylate p65’s S468 and enhances the transcriptional activation of NF-κB (Mattioli et al., 
2006). 
Other residues involved in p65’s phosphorylation and regulation include S205, S281, 
S311, S529, T254, T435 and T505.  S311, T505 and S529 were shown to be phosphorylated by 
protein kinase C-zeta (PKCζ), Chk1 and casein kinase 2 (CK2), respectively (Duran et al., 2003; 
Rocha et al., 2005; Wang et al., 2000).  S205, T254, S281 and T435 are also phospho-acceptor 
sites, but their kinases are not yet known.  Phosphorylation of p65 on some of these residues 
(S205, S281, S311 and S529) enhances the transcriptional activity of selective NF-κB-dependent 
genes. On the contrary, T435 and T505’s phosphorylation was shown to inhibit NF-κB activity 
(Huang et al., 2010).  
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Figure 1.5  Posttranslational modifications of RelA (p65). (A) Known phosphorylation sites 
of RelA and their corresponding kinases. (B) Known acetylation sites of RelA and their 
corresponding acetyltransferases. (C) Known methylation sites of RelA and their corresponding 
methyltransferases. Question marks denote unknown enzymes. Adapted from Huang et al., 2010. 
 
1.5.1.2  Acetylation 
 Acetylation is another important posttranslational modification of p65. Most acetylation 
events occur in the nucleus, where acetyltransferases mediate addition of the acetyl group to 
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lysine residues. Like phosphorylation, acetylation of p65 is a reversible process and plays a role 
in altering the DNA binding and transcriptional activity of NF-κB (Huang et al., 2010). 
 Seven lysine residues of p65 have been identified to be acetylated including lysine 122, 
123, 218, 221, 310, 314 and 315 (Figure 1.5B). While most lysine residues are acetylated by 
p300/CBP,  K122 and K123 can also be modified by PCAF (Kiernan et al., 2003). Acetylation of 
p65 on different lysines appears to affect the function of NF-κB differently. For example, 
acetylation at K221 enhances the DNA binding of NF-κB while acetylation at K122 and K123 
reduces p65 binding to the κB promoters (Chen et al., 2002). While acetylation of K218 impairs 
NF-κB association with IκBα, acetylation of K310 does not affect DNA binding nor IκBα 
association. Interestingly, acetylation of K314 and K315 does not involve in regulating NF-κB 
shuttling or DNA binding, but appears to modulate the expression of specific sets of NF-κB 
target genes (Buerki et al., 2008). 
1.5.1.3  Methylation 
 In addition to phosphorylation and acetylation, methylation has also emerged as an 
important modification for the regulation of nuclear NF-κB function. Most methylation events 
occur on lysine residues but some arginine can also be modified. Depending on the position as 
well as the state of methylation (mono-, di-, or tri-methylation), this can cause different effects 
on the function of NF-κB (Huang et al., 2010). 
 Several p65’s lysine methyltransferases have been described (Figure 1.5C). These 
enzymes usually modify more than one lysine residue. For example, Set9 mono-methylates p65 
at K37, K314 and K315 (Yang et al., 2009). Interestingly, while methylation of p65 by Set9 at 
K314 and K315 negatively affects the function of NF-κB by inducing a ubiquitin-mediated 
degradation of promoter-bound p65, methylation at K37 is implicated in the activation of a 
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subset of NF-κB target genes by stabilizing the binding of NF-κB to its enhancers (Ea and 
Baltimore, 2009). Another p65’s methylase is NSD1. NSD1 mono-methylates K218 and di-
methylates K221. Methylation of p65 by NSD1 enhances the transcriptional activity of NF-κB 
(Lu et al., 2010). 
 Besides lysine methyltransferases, arginine methyltransferases have also been implicated 
in regulating NF-κB functions. Three p65’s arginine methyltransferases, PRMT1, PRMT2 and 
PRMT4 have been identified so far. It appears that not only is their enzymatic activity essential 
but also these arginine methyltransferases can bind and act as p65’s cofactors (Covic et al., 2005; 
Ganesh et al., 2006).     
1.5.2  Interacting proteins 
 Besides being regulated by posttranslational modifications, NF-κB’s cofactors also play a 
crucial role in its stimulus- and promoter-specific transcriptional regulation. A vast array of 
coregulators, including coactivators and corepressors, have been identified (Wan and Lenardo, 
2010). One example of such coactivators is the astrocyte elevated gene-1 (AEG-1) (Sarkar et al., 
2008). AEG-1 interacts with NF-κB’s p65 in a TNFα-dependent manner. Binding of AEG-1 
helps facilitate the interaction of NF-κB with the basal transcriptional machinery at the promoter 
of the IL-8 gene and thus promoting its expression. An example of NF-κB’s corepressors is the 
inhibitor of growth 4 (ING4) (Nozell et al., 2008). ING4 is recruited to NF-κB’s promoters, 
which on the one hand results in inhibition of p65 phosphorylation and p300 binding, but on the 
other hand enhances the level of HDAC-1 at these promoters and thus negatively regulating NF-
κB’s transcriptional activity. 
 Interactions between NF-κB dimers and a variety of transcription factors have also been 
described. For example, some NF-κB -dependent genes induced by LPS also require the b-ZIP 
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transcription factor JunB (Krappmann et al., 2004). Cooperative interactions have also been 
shown between NF-κB and zinc-finger-containing transcription factors such as Sp1 and other b-
ZIP factors such as C/EBP b (Perkins, 1997). The range of such interactions is likely to be large 
and this diversity plays a role in determining the heterogeneity of NF-κB -dependent gene 
expression.  
 
1.6   Cellular functions of NF-κB 
 Studies over the past 25 years have led to identification of about a hundred genes directly 
regulated by NF-κB. These genes play important roles in many cellular pathways including 
immune development and function, cell proliferation and survival (Hoffmann and Baltimore, 
2006). Examples of genes encoding inflammatory mediators are the pro-inflammatory cytokines 
TNFα, IL-1, and IL-12 and chemokines such as monocyte chemotactic protein -1 (MCP-1), 
interferon-inducible protein-10 (IP-10), and regulated upon activation, normal T-cell expressed 
and presumably secreted (RANTES). In addition, a large number of NF-κB -dependent genes 
contribute to the innate immune response such as the anti-microbial peptide b-defensin-2 or the 
C-reactive protein (Hoffmann and Baltimore, 2006). NF-κB also involves in regulating the 
expression of genes in the programmed cell death pathway. Most of the genes in this pathway, 
when upregulated, are known to have anti-apoptotic function and they work by interfering with 
c-Jun N-terminal kinase signaling (e.g. GADD45β), by preventing the accumulation of reactive 
oxygen species (e.g. MnSOD, FHC) and protecting the mitochondria (Bcl2 family members), or 
by inhibiting caspases (e.g. inhibitors of apoptosis  (IAPs), cellular FLICE inhibitory protein (c-
FLIP)) (De Smaele et al., 2001; LaCasse et al., 1998; Micheau et al., 2001; Pham et al., 2004). 
Other NF-κB’s target genes involved in tissue remodeling (e.g. matrix-metalloproteinases) and 
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cell cycle regulatory proteins (e.g. cyclin D) have also been reported (Hinz et al., 1999; Okamoto 
et al., 2004). 
 
1.7   Physiological roles of NF-κB  
 At the tissue level, NF-κB plays important roles in the development and differentiation of 
the immune system, in the dynamic regulation of local and systemic immune activity as well as 
in the development and survival of the liver. The following sections will provide details on this 
aspect of NF-κB. 
1.7.1  Lymphocyte biology 
 Mice knock-out studies have found p65 and c-Rel to be critical for lymphocyte 
development and function (Horwitz et al., 1997; Kontgen et al., 1995). While cRel-deficient 
mice have normal numbers of many lymphocyte subclasses, mature lymphocytes, however, fail 
to activate certain pathways such as B- and T-cell proliferation and isotype switching. On the 
other hand, mice lacking p65 show embryonic lethality during embryonic day E14-15. The 
canonical NF-κB  pathway plays an important role in providing survival and proliferative signals 
to lymphocytes, thus facilitating early B- and T-cell development (Siebenlist et al., 2005). In 
addition, this pathway is also required for the efficient development of unique T-cell 
subpopulations, such as natural killer T cells and CD4+CD25+ regulatory T cells (Schmidt-
Supprian et al., 2004).  
1.7.2  Secondary lymphoid organ development 
 Lymphocyte development also requires proper functioning of secondary lymphoid 
organs. Both canonical and non-canonical pathways are important for the secondary lymphoid 
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organogenesis as mice lacking p65, RelB, p50 or p52 are deficient in peripheral lymph nodes 
(Alcamo et al., 2002; Lo et al., 2006; Yilmaz et al., 2003).  Lack of NF-κB  activity in stromal, 
epithelial, or dendritic cell populations in thymus and spleen also causes developmental defects 
in the B- and T-cell compartments, which can result in defective deletion of auto-reactive T cells 
and establishment of central tolerance (Weih and Caamano, 2003).  
1.7.3  Role of NF-κB  in liver development and survival 
 NF-κB has an important role in liver physiology and function.  p65-deficient mice show 
embryonic lethality during embryonic day E14-15 due to massive apoptosis in the fetal liver due 
to TNFα exposure (Horwitz et al., 1997).  The hepato-protective role of NF-κB  is due to its 
ability to activate genes that can prevent TNFα induced cell death (Sun and Karin, 2008). In 
hepatocytes, the most critical anti-apoptotic protein induced by NF-κB appears to be c-FLIP 
(Chang et al., 2006). FLIP inhibits apoptosis by interfering with caspase-8 activation (Micheau 
and Tschopp, 2003). In addition, induction of NF-κB -dependent genes encoding antioxidants 
such as SOD2 and ferritin heavy chain prevents the accumulation of reactive oxygen species, 
which can cause both apoptosis and necrosis (Kamata et al., 2005; Pham et al., 2004). 
 
1.8   NF-κB  in diseases 
 Aberrant NF-κB regulation has been observed in various disease including chronic 
inflammation and different types of cancers. High levels of active nuclear NF-κB are found in 
the affected organs of patients with rheumatoid arthritis, asthma, inflammatory bowel diseases, 
liver fibrosis and cirrhosis (Chen and Greene, 2004; Sun and Karin, 2008). Also, because of its 
role in regulating expression of many important genes, NF-κB  is implicated in malignancy 
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processes including tumor cell proliferation through its ability to induce proto-oncogenes such as 
cyclin D1 and c-Myc, metastasis through expression of cellular adhesion molecules and matrix 
metalloproteinases; angiogenesis through regulation of vascular endothelial growth factor; and 
cell immortality through regulating telomerases (Perkins and Gilmore, 2006). Constitutively 
active forms of NF-κB are frequently detected in many cancers including both solid and 
hematopoietic tumors (Baud and Karin, 2009).  
 It is believed that NF-κB  and the NF-κB pathway play a key role linking inflammation 
and tumor development (Karin, 2009). In most tumors, NF-κB is activated not due to intrinsic 
mutations but in response to inflammatory stimuli originating from the microenvironment. 
Mutations that endow RelA, c-Rel, or other NF-κB proteins with transforming activity are rare 
and mainly limited to lymphoid malignancies. A good example of inflammation-linked cancers 
is hepatocellular carcinoma (HCC), the most common form of liver cancer. Most HCC develops 
in the context of chronic hepatitis caused by either HBV or HCV viral infection (Sun and Karin, 
2008).   
 
1.9   Targeting NF-κB and its pathway in cancer therapy 
 NF-κB transcription factors play a key role in many physiological processes, such as 
innate and adaptive immune responses, cell proliferation, cell death, and inflammation. Aberrant 
regulation of NF-κB and its signaling pathways have been implicated in cancer development and 
progression, as well as in resistance to chemo- and radiotherapy. 
 Drugs that block NF-κB are currently in clinical trials with promising results. In murine 
xenograft models, proteasome inhibitors were shown to have significant anti-tumor activity and 
in squamous cell carcinoma tumor models, another inhibitor, PS-341, inhibits cell survival, 
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tumor growth and angiogenesis (Richardson et al., 2004; Yin et al., 2005). Most proteasome 
inhibitors work by blocking NF-κB nuclear localization through inhibition of IκBα degradation 
and processing of the p105 NF-κB precursor. However, as the major proteolytic system in 
eukaryotic cells, the ubiquitin–proteasome pathway controls the breakdown of many cellular 
proteins, thus inhibiting this pathway will affect other physiological processes. Other molecules 
have been shown to inhibit NF-κB including a peptide that blocks the interaction of IKKγ with 
the catalytic subunits of IKK, the non-steroidal anti-inflammatory drug (NSAID) sulindac, 
cyclopentenone prostaglandins, arsenic trioxide, thalidomide, a variety of anti-oxidants, natural 
products such as parthenolide and resveratrol, and pharmaceutically developed synthetic small-
molecule inhibitors of the IKK complex (Baldwin, 2001; Kapahi et al., 2000; Keifer et al., 2001; 
Yamamoto and Gaynor, 2001). Specially, resveratrol was shown to induce apoptosis of Ras-
transformed cells, and sulindac also induced cell death in certain transformed cells. Arsenic 
trioxide, which directly modifies a critical cysteine of IKK, has shown efficacy in several 
hematological malignancies. Another IKK inhibitor, PS-1145, inhibits multiple myeloma cell 
proliferation but not as effectively as the proteasome inhibitor PS-341 (Hideshima et al., 2002). 
Overall, these data underscore the potential relevance of targeting NF-κB in cancer by blocking 
different constituents in the NF-κB signal-transduction pathway. However, one drawback all 
these inhibitors suffer is selectivity as many of them not only block NF-κB but also affect other 
cellular pathways as well.   
 
1.10   Toward a better understanding of the NF-κB gene regulation 
NF-κB has emerged as a central player in a variety of physiological functions. It was 
initially thought that each NF-κB -inducing stimulus is capable of activating a specific gene 
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expression program by causing the degradation of a specific IκB protein, leading to the release of 
a specific NF-κB dimer that is capable of binding a subset of κB sites. However, there is little 
functional evidence for specificity due to IκB isoform-specific degradation by a particular 
stimulus or due to interaction between different NF-κB isoforms and κB sites. In fact, NF-κB  
dimers display overlapping κB-site recognition properties (Hoffmann and Baltimore, 2006). So 
how do cells achieve cell type-, stimulus and time-dependent responses employing a single 
signaling pathway? The NF-κB family of transcription factors provides a number of interesting 
paradigms for combinatorial control of gene regulation (Natoli and De Santa, 2006). 
Accumulating evidence indicates that specificity in NF-κB-regulated gene expression is 
generated at multiple levels including at the receptor level where each receptor can activate a 
specific signaling network and at the promoter level where each promoter only allows NF-κB 
with proper posttranslational modifications or cofactor recruitment to bind.    
Alternative NF-κB stimuli can induce different sets of NF-κB-dependent genes and thus 
producing distinct biological responses. For example, while NF-κB activity induced by TNFα is 
rapidly attenuated due to the negative feedback mechanism involving the synthesis of its 
inhibitor IκB, NF-κB activity induced by LPS is sustained due to an autocrine loop of LPS-
dependent TNFα induction and secretion. In addition, like many transcription factors, NF-κB is 
subject to posttranslational modifications. These modifications including phosphorylation, 
acetylation and methylation provide additional layers of regulation of NF-κB activity and its 
selective induction of target genes. Also, besides binding key players in its activation pathway, 
NF-κB has been shown to interact with many cofactors and these proteins can influence NF-κB  
activity in different ways. They can act as coactivitors to enhance NF-κB transcriptional activity 
or as co-repressors to suppress its activity. Finally, synergistic interaction between NF-κB and 
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partner transcription factors can also play a role in shaping specific aspects of the NF-κB  
response, such as stimulus- and tissue-specific expression of target genes. In the following 
chapters, studies of some of these NF-κB regulatory events are described.  
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2.1   INTRODUCTION 
     Since its discovery more than 20 years ago (Sen and Baltimore, 1986), nuclear factor-
kappa B (NF-κB) has become one of the most intensively studied eukaryotic transcription 
factors. In mammalian cells, NF-κB has diverse functions in regulating inflammation, immunity, 
apoptosis and proliferation (Baldwin, 1996; Hayden and Ghosh, 2008; Karin et al., 2002; 
Schmitz et al., 2004).and is expressed by five known NF-κB/REL genes, RELA, c-REL, RELB, 
NFΚB1, and NFΚB2, that give rise to seven protein products:  RELA (p65), c-REL, RELB 
p105/p50, and p100/p52, (p50 and p52 are the cleaved forms of p105 and p100, respectively).  In 
cells, NF-κB proteins interact to form homo- and heterodimers, the most abundant of which is a 
p65/p50 heterodimer containing RELA and the cleaved form of the NFKB1 gene product 
(Hayden and Ghosh, 2004). Dimerization is mediated by an N-terminal REL-homology domain 
(RHD) of ~300 amino acids that is present in all NF-κB proteins and is also responsible for 
binding to DNA and to the IκB family of NF-κB inhibitors (Hacker and Karin, 2006).   
  NF-κB is activated by a variety of stimuli including pro-inflammatory cytokines, growth 
factors, DNA-damaging agents and viral proteins (Hayden and Ghosh, 2008; Hoffmann and 
Baltimore, 2006). In the absence of these stimuli, NF-κB dimers are sequestered in the cytoplasm 
through association with IκBs. NF-κB activation via the canonical pathway involves 
phosphorylation of IκB by IκB kinase (IKK), a modification that marks IκB for ubiquitin-
mediated degradation by the proteosome.  This liberates the p65/p50 dimer from its inhibited 
state, allowing translocation into the nucleus and subsequent binding to the promoters of genes 
containing κB elements (Perkins and Gilmore, 2006).  Analysis of promoters regulated by NF-
κB has shown that κB sites exhibit a loose consensus sequence conforming to the motif G-5G-4G-
3R-1N-1N0Y+1Y+2C+3C+4  (where R is purine, Y is pyrimidine and N is any base) (Lenardo and 
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Baltimore, 1989). Thousands of matches to this consensus are found in human and chimpanzee 
genomes (Kasowski et al., 2010) but the κB sequences actually involved in gene expression 
appear to be highly conserved between mouse and human (Leung et al., 2004) implying that the 
consensus sequence captures only part of the information controlling NF-κB binding selectivity.  
      The early cytoplasmic events that lead to nuclear translocation of NF-κB have been studied 
in considerable detail but current understanding of NF-κB regulation does not fully explain its 
temporal, ligand and cell-type specificity. In addition to being modified by multiple cytosolic 
kinases, events downstream of NF-κB nuclear transport such as the recruitment of cofactors 
control transcriptional activity (Chen and Greene, 2004; Wan and Lenardo, 2010).  Initially, it 
was thought that the composition of NF-κB dimers determined which promoter sequences would 
be bound but it was subsequently shown that different dimers bind κB sites with little differential 
selectivity (Natoli and De Santa, 2006).  In addition, subunits in NF-κB hetero- and homo-dimers 
can exchange with the unbound nuclear pool at a single promoter site during the course of a 
response (Saccani et al., 2003). It now seems that κB sequences specify which cofactors can 
form productive interactions with DNA-bound NF-κB and that it is these co-factors that are 
largely responsible for target selectivity (Leung et al., 2004). For example, the astrocyte elevated 
gene-1 (AEG-1) protein acts as an NF-κB co-activator for expression of the interleukin 8 gene 
and the inhibitor of growth 4 protein (ING4;, which binds p65 directly)  acts as an NF-κB 
corepressor (Nozell et al., 2008; Sarkar et al., 2008).  
        Several types of post-translational modification have been identified as regulators of NF-κB 
activity.  In the case of p65, phosphorylation, acetylation and methylation alter the efficiency of 
binding to DNA and association with transcriptional coregulators. For examples, p65 
phosphorylation at serine 276 by PKAc or MSK1, or at serine 311 by PKCζ enhances p65 
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binding to CBP and p300, components of the basic transcriptional machinery (Duran et al., 2003; 
Vermeulen et al., 2003; Zhong et al., 1997). Overall, nine sites of serine/threonine 
phosphorylation on p65 have been reported to date. Multiple kinases modify these sites in 
response to a wide variety of stimuli and in some cases, a single kinase phosphorylates multiple 
p65 sites (Chen and Greene, 2004; Huang et al., 2010).  For example, p65-S276 is 
phosphorylated in response to TNF-α by the catalytic subunit of protein kinase A (PKAc) or in 
the nucleus by mitogen- and stress-activated protein kinase-1 (MSK-1) or by the 
serine/threonine-protein kinase Pim-1 (Nihira et al., 2010; Vermeulen et al., 2003; Zhong et al., 
1997).  The IKKβ kinase phosphorylates p65 on residues S468 and S536, which results in 
inhibition or enhancement of gene expression depending on cellular context (Buss et al., 2004; 
Schwabe and Sakurai, 2005). 
 Given the complexity of NF-κB biology, a full understanding of its regulation will 
require studying proteins that associate with and modify its subunits and determining the 
consequences of binding and modification for transcriptional activity.  Here we use affinity 
purification and mass spectrometry of epitope-tagged p65 expressed at its endogenous locus to 
identify potential NF-κB binding partners. Among the novel interacting partners arising from this 
analysis we focus on STK38 and STK38L (serine-threonine kinase 38 and 38-like), members of 
the AGC kinase family. These kinases are highly conserved from yeast to humans and have been 
implicated in diverse cellular processes such as mitotic exit, cytokinesis, centrosome duplication 
and apoptosis (Hergovich et al., 2008; Hergovich et al., 2006; Vichalkovski et al., 2008). 
Substrates of STK38 and STK38L in mammalian cells have been largely unexplored but we 
show here that the kinases can phosphorylate p65 in vitro and that their kinase activity is 
important for induction of multiple NF-κB-dependent inflammatory genes including TNF and 
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LTB. Our results suggest that STK38 and STK38L are new binding partners, modifiers and co-
activators of NF-κB.  
 
2.2   RESULTS 
2.2.1  STK38/STK38L interact with the p65 subunit of NF-κB 
 To identify proteins that interact with p65, a FLAG-HA tandem affinity tag was knocked 
into the 3’ end of RELA gene in an HCT116 colorectal cancer cell line using an adeno-
associated virus protocol developed in the Vogelstein and Bunz laboratories (Kohli et al., 2004; 
Topaloglu et al., 2005).  The knock-in construct and approach to identifying positive clones is 
shown in Figure 2.1. Affinity purification was performed on anti-FLAG resins using whole-cell 
extracts from cells expressing FLAG-HA-RELA. Eluted proteins were then subjected to liquid 
chromatography- mass spectrometry (LC-MS) which resulted in the identification in MS spectra 
multiple well characterized p65 interacting-proteins (p50, p52, RelB, c-Rel, IκB isoforms, and 
multiple 14-3-3 proteins (Bouwmeester et al., 2004)), thus validating our tagging and 
purification strategy (we note that this strategy does not distinguish between direct and indirect 
p65 interactors). Both untreated and TNF-α treated cells were examined, but few differences in 
the set of bound proteins was observed. However, LC-MS analysis was not carried out in a 
manner that would allow samples to be compared for quantitative rather than qualitative 
differences in the spectrum of bound proteins; our approach was focused on obtaining the longest 
list of candidate binding partners.   
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Figure 2.1  Generation of a knock-in cell line expressing tagged p65/RELA. (A) Design of 
knock-in construct based on adeno-associated virus methods from the Vogelstein and Bunz 
laboratories (Rago et al., 2007).  A tandem affinity FLAG-HA tag (labeled “Tag ”) was designed 
to be inserted at the C-terminus of p65. Abbreviations: LHA/RHA: Left/right homology arm. 
SA: splice acceptor; INT: intron; IRES: internal ribosomal entry site; neo: neomycin resistance 
gene; pA: poly A. IS: intergration site. Inset image is a representative agarose gel from PCR 
screening for clones in which homologous recombination had taken place. PCR primers were 
specific for the left arm or right arm as indicated.  Positive clones were infected with adenovirus 
carrying Cre-recombinase expression vector to remove the neo selection cassette and ensure 
correct p65 expression.   
 
 Among the putative p65 binding proteins identified by MS, four previously unreported 
proteins were reproducibly isolated in our affinity purification procedure: CCT6A (T-complex 
protein 1, zeta subunit), STK38 (Serine/threonine-protein kinase 38, or NDR1), STK38L 
(Serine/threonine-protein kinase 38-like, or NDR2), SERBP1 (Plasminogen activator inhibitor 1 
RNA-binding protein).  We also identified PRMT1 (Protein arginine N-methyltransferase 1), 
which was shown during the course of our work to bind p65 and regulate transactivation (Hassa 
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et al., 2008). An extended list of candidate interacting proteins is presented in supplemental 
Table-S-2.1. cDNAs encoding each of the four new proteins as well as PRMT1 were cloned into 
vectors carrying a tandem calmodulin/streptavidin binding peptide affinity tag  (CBP-SBP 
derived from Stratagene’s pNTAP vectors) to allow affinity isolation and a StrepTag II tag to 
allow detection by Western blotting (Figure 2.2A). In the case of proteins whose molecular 
weights were similar to that of p65 (CCT6A, STK38, STK38L and SERBP1), an ~30kD N-
terminal GFP tag was added to facilitate separation on SDS PAGE gels. p65 and tagged binding 
proteins were independently transiently transfected into 293T cells, lysates containing over-
expressed p65 or candidate interacting proteins were mixed and affinity isolations were 
performed using resin carrying crosslinked streptavidin. Under these conditions we observed that 
all five proteins bound to p65 with three, STK38, STK38L and CCT6A, binding to a greater 
extent than the others (Figure 2.2B). When we repeated affinity isolations under more stringent 
conditions in which only the tagged interactors were over-expressed and p65 was present at 
endogenous levels, binding to p65 was most convincing for STK38 and STK38L (Figure 2.2C).  
We therefore concentrated our analysis on STK38 and STK38L (referred to as STK38/38L 
below) without ruling out the possibility that the other proteins are also able to associate with 
p65. Moreover, when we compared levels of ectopically-expressed and tagged STK38/38L 
bound to p65 in HCT116 before and after treatment with 100 ng/ml TNF-α for 3 and 5 hours 
(Figure 2.2D), no significant differences were observed. We conclude that STK38 and STK38L 
bind to p65 independent of stimulation with TNF-α.  
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Figure 2.2  Verification of p65 binding proteins by co-precipitation. (A) Tagging strategy for 
confirming p65 binding by proteins identified as interactors by mass spectrometry.  cDNAs 
encoding candidate p65-binding proteins were cloned into a pNTAP vector engineered to contain 
an N-termimal tandem affinity tag comprising a camodulin binding peptide (CBP; pink), a 
Streptavidin binding peptide (SBP; red), and a StrepTag II (yellow).  In the case of proteins 
whose molecular weights were similar to that of p65, GFP was inserted at the C-terminus to 
increase apparent mass by ~30 kD.  (B) Reciprocal immunoprecipitation was performed where 
both candidate proteins and p65 were ectopically-expressed in 293T cells and Strep resin was 
used to pull down the candidate proteins, control contains only p65 and resin. The same amount 
of p65-containing lysates was added in each IP sample. Abbreviations are as follows: PRMT1, 
protein arginine N-methyltransferase 1; CCT6A, T-complex protein 1, zeta subunit; STK38, 
serine/threonine-protein kinase 38 (or NDR1); STK38L, serine/threonine-protein kinase 38-like 
(or NDR2); SERBP1, plasminogen activator inhibitor 1 RNA-binding protein. CCT6A, STK38, 
STK38L and SERBP1 constructs include GFP. (C) Reciprocal immunoprecipitation as in (B) in 
which only candidate proteins were overexpressed in 293T cells while p65, expressed at 
endogenous levels, was purified from HCT116 cells. Lysates containing an overexpressed 
candidate protein and endogenous p65 were mixed prior to immunoprecipitation, control 
contains only endogenous p65 and resin. (D) Immunoprecipitation as in (C), but using STK38 
and STK38L as bait proteins and p65 from cells treated with 100 ng/mL TNF-α for various 
times, as indicated. Lower plot quantifies the level of bound, normalized to the amount at 0 hr. 
(that is, in the absence of TNF-α). Error bars represent the standard deviation of the mean of 
biological duplicates.   
 
2.2.2  STK38/STK38L phosphorylate p65 in vitro 
 To determine whether STK38 and STK38L phosphorylate p65, we performed in vitro 
kinase assays using enzymes and substrates isolated from normally growing 293T cells (kinases 
were isolated by affinity purification on Streptavidin resin and HA-tagged p65 was immuno-
purified using anti-HA resin).  p65 substrate was added at about twice the level of STK38/38L 
kinases (in mass terms) based on protein quantification using Coomassie stained SDS-PAGE 
gels. We observed significant auto- and trans phosphorylation of STK38, STK38L and p65; 
levels of radiolabel incorporation did not change significantly when kinases were purified from 
untreated cells or cells treated with either TNF-α or insulin for 6 hours (see supplemental Figure 
S-2.1). To demonstrate that the vitro kinase assays selectively measured STK38/38L activity, we 
generated STK38-K118A and STK38L-K119A mutants carrying lysine-to-alanine changes in the 
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catalytic site that rendered the kinases inactive. When in vitro kinases assays were performed 
with affinity purified STK38-K118A or STK38L-K119A, no increase in p65 phosphorylation 
was observed relative to negative control reactions (compare lanes 2, 4 and 5, Figure 2.3A); 
residual phopshorylation in control samples was likely due to low levels of contaminating 
kinases that co-purified with the p65 substrate.  
 To identify the sites at which STK38/38L modifies p65, we performed in vitro kinase 
assays followed by phospho-mass spectrometry.  This analysis showed T308, S311 and S356 to 
be high certainty sites for phospho-addition, and S319, S338 and T458 to be less certain sites; no 
significant differences in the pattern of modification were observed between STK38 or STK38L. 
We mutated T308, S311 and S356 individually to alanine and repeated the vitro kinase assay. In 
each case we observed a roughly two-fold reduction in the levels of phosphorylated p65 with no 
change in the level of autophosphorylated kinase (which therefore serves as an internal control; 
Figure 2.3B).  A double p65-S311A/ S356A mutant was not obviously less highly modified than 
single mutants and examination of mass spectrometry data did not uncover peptides doubly 
phosphorylated on T308 and S311.  We conclude that p65 is phosphorylated in vitro by 
STK38/38L on T308, S311 and S356, probably at the level of one phosphorylation event per p65 
molecule and that other residues are also modified at a lower stoichiometry.  We speculate that 
when preferred phosphorylation sites are mutated, other residues become substrates. This is 
commonly observed for kinases that bind to their substrates (e.g. (Jeffery et al., 2001)).   
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Figure 2.3  In vitro kinase assay. (A) Tagged STK38, STK38L kinases and p65 substrate were 
expressed in 293T cells. After affinity purification, proteins were run on SDS-PAGE gel and 
stained with Coomassie blue to estimate their relative levels. In-vitro kinase assays were 
54 
 
performed in which the amount of substrate added was at least twice that of kinase. The STK38 
K118A and STK38L K119A represent kinase-dead mutants. All samples were run on the same 
gel but cut from different lanes. (B) Three p65 phosphorylation sites, T308, S311 and S356, were 
identified with high certainty by phospho-mass spectrometry of p65 phosphorylated in vitro. p65 
mutants were then expressed in cells and kinase assays performed as described in (A); the 
amounts of different p65 substrates were similar in each reaction. Lower plot quantifies 
phosphorylation of various substrates, normalized to p65 wild-type. Error bars represent the 
standard deviation of the mean of biological duplicates. 
 
2.2.3  STK38 affects p65 gene specific regulation 
 To determine whether phosphorylation of NF-κB by STK38/38L is involved in gene 
transcription, we created cell lines in which either p65 or the STK38/38L kinases were stably 
knocked down using RNAi.  Because STK38 and STK38L are highly homologous (~87% 
identical) and have previously been shown to compensate for each other in knockout animals 
(Cornils et al., 2010; Hergovich et al., 2008), we targeted both proteins in a single cell line.  
shRNA directed against STK38L was expressed constitutively from a pGIPZ lenti-vector 
(Sigma) while an inducible shRNA against STK38 derived from a pTRIPZ lenti-vector (Sigma) 
was expressed under control of a Tet promoter that could be induced by adding doxycycline; 
shRNA against p65/RELA was independently expressed in a separate cell line under the same 
inducible Tet promoter.  By Western blotting of extracts from shRNA expressing cells, we 
observed 60-80% reductions in the levels of STK38 and p65 proteins and ~60% reduction in 
STK38L, depending on the duration and concentration of doxycycline treatment (Figure 2.4A). 
Using Affymetrix expression microarrays we then measured changes in TNF-α –mediated gene 
expression following exposure of p65-knockdown or STK38/38L-knockdown cells to 2 μg/ml 
doxycycline for five days.  We reasoned that genes co-regulated by p65 and STK38/38L should 
display similar changes in expression in the two knockdown lines as compared to control cells 
expressing non-specific shRNA.  By this criterion, genes encoding lymphotoxin beta (LTB) and 
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tumor necrosis factor alpha (TNF) were selected for further analysis. Both genes are known from 
previous studies to be upregulated by NF-κB in the presence of TNF-α (Kuprash et al., 1996; 
Shakhov et al., 1990).  A list of genes upregulated by TNF-α stimulation is presented in 
supplemental Table-S-2.2. Extended lists of genes whose expressions were affected by only p65 
knockdown or STK38/38L double knockdown were presented from supplemental Table-S-2.3 to 
Table-S-2.6.  
Real-time PCR assays confirmed that following exposure of cells to 100 ng/ml TNF-α for 
6 hours, LTB was induced ~28 ± 4 fold (representing the mean and standard deviation of the 
mean of biological duplicates) in cells expressing a non-specific control RNA, but only ~6 ± 0.2 
fold in cells in expressing shRNA directed against p65 and ~12 ± 2 in cells co-expressing 
shRNA against STK38/38L (Figure 2.4B). A similar pattern of regulation was observed for the 
TNF gene (Figure 2.4C). In contrast, full induction of another NF-κB regulated gene, IκBα, was 
observed to require p65 but not STK38/38L (Figure 2.4D). This implies that STK38/38L kinases 
are involved in the induction of some but not all NF-κB-regulated genes. 
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Figure 2.4  Genes co-regulated by STK38 and p65 in cells treated with 100 ng/mL TNF-α. 
(A) Western blots of STK38, STK38L and p65 protein in cells expressing non-specific shRNA 
(NS KD) or shRNA directed against STK38/38L or p65 as indicated. shRNAs were induced by 
treating cells with 2 μg/ml doxycycline for five days. No significant reduction in p65 protein 
levels were observed in STK38/38L KD cells as compared to NS KD cells. All samples were run 
on the same gel but cut from different lanes. (B, C) Real-time PCR was performed to confirm the 
microarray data. mRNA samples from NS KD, STK38/38L KD and p65 KD cells treated with 
100 ng/mL TNF for 0 and 6 hours were collected for qPCR. Fold induction was calculated based 
on the difference in the number of cycles between the TNF-treated and untreated cells. Error bars 
represent the standard deviation of the mean of biological duplicates. (D) Expression of IκBα is 
regulated by p65 but not STK38/38L. 
 
 To demonstrate the specificity of shRNA-mediated STK38 knockdown, we carried out 
rescue experiments in which an RNAi-resistant form of STK38 was transiently expressed in 
STK38/38L knockdown cells. To avoid artifacts associated with over-expression, cells were 
examined in which total STK38/38L proteins levels (representing residual endogenous protein 
expression plus ectopic expression) was at or below that of wild-type cells (Figure 2.5A, B). We 
observed that expression of RNAi-resistant STK38 in shRNA-producing cells was sufficient to 
restore capacity to induce LTB up to wild-type levels upon TNF-α ligation (Figure 2.5C); rescue 
was also observed for TNF-α-mediated induction of the TNF gene (Figure 2.5D).  In contrast, re-
expression of a kinase-dead STK38-K118A at a similar level did not rescue the induced 
expression of either gene above the negative control. However, co-immunoprecipitation 
experiments showed that STK38-K118A bound to p65 to a similar extent as wild-type STK38 
(Figure 2.5G), suggesting that kinase-dead STK38-K118A is correctly expressed and folded. 
Basal expression levels for LTB and TNF mRNA were unaffected by STK38/38L knockdown, 
but re-expression of either wild-type or kinase-dead STK38/38L increased TNF mRNA levels by 
~1.7 fold (Figure 2.5E, F).  The reasons for this are unknown but might reflect the sensitivity of 
the TNF regulatory circuit to transfection conditions.  Importantly, changes in basal gene 
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expression do not affect our conclusions since the data shown in  Figure 2.5C and D represent 
fold-changes between the TNF-treated and untreated cells.  We conclude that full induction of 
LTB and TNF (by exogenous TNF-α) requires both p65 and the kinase activity of STK38/38L. 
STK38/38L kinase activity is not required for binding to p65 however, suggesting that a 
downstream process is involved.   
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Figure 2.5  shRNA rescue phenotypes. (A) Western blots showing the expression of STK38 in 
NS KD and STK38/38L KD cells and in cells in which RNAi-resistant forms of either STK38 or 
STK38 K118A were re-expressed. Re-expressed proteins are larger by ~10 kDa due to the 
presence of the NTAP tag. All samples were run on the same gel but cut from different lanes. (B) 
Quantification of rescue level from (A), the level of STK38 in NS KD was normalized to 1. 
Error bars represent the standard deviation of the mean of biological duplicates. (C, D) Rescue of 
STK38/38L KD phenotypes in cells by re-expression of either STK38 wild-type (WT) or kinase-
dead (K118A) vectors (refer to Materials and Methods for experimental details). Cells were 
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treated with 100 ng/mL TNF for 6 hours before mRNA isolation and analysis by real-time PCR. 
Fold induction was calculated based on the difference in the number of cycles between the TNF-
treated and untreated cells. (+) denotes STK38/STK38L shRNA. Error bars represent the 
standard deviation of the mean of biological duplicates. (E, F) mRNA level in various cells 
populations in the absence of TNFα exposure.  In the case of TNF, transfected cells had higher 
basal gene expression compared to untransfected cells. (G) Pull down of STK38 and STK38 
K118A shows that wild type STK38 and kinase dead STK38 K118A bind p65 equally well.  
 
 We attempted to increase the extent to which STK38/38L knockdown inhibited LTB and 
TNF expression by increasing the duration of shRNA expression. When shRNA-expressing cells 
were exposed continuously to doxycycline for 7 days without changing media, STK38 was 
present at <10% of wild-type levels and LTB and TNF inducibility by TNF-α was almost 
completely abolished. However, this defect could not be rescued by re-expression of wild-type 
STK38, implying that shRNA-mediated STK38 knockdown had lost its selectivity (data not 
shown).  We therefore chose to work with the less severe, but demonstrably selective knockdown 
phenotypes.   
 
2.2.4  Functional role for p65 residues modified by STK38/38L  
 To determine whether modification of p65 by STK38/38L plays a role in gene regulation, 
we re-expressed p65 carrying serine- or threonine-to-alanine point mutations in cells in which 
endogenous p65 had been knocked down by shRNA (Figure 2.6A, B).  In agreement with 
previous data (Karin and Lin, 2002; Kuprash et al., 1999) we observed that even modest p65 
over-expression (to levels ~1.5X that of wild-type) caused activation of NF-κB-responsive genes 
even in the absence of an exogenous stimulus. This presumably arises because the concentration 
of endogenous plus ectopic NF-κB overwhelms the ability of IκB to act as an inhibitor. LTB and 
TNF mRNA levels were therefore measured in p65 knockdown cells re-expressing p65 mutants 
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in the absence of TNF-α treatment. Data were expressed as the fold-difference in LTB and TNF 
mRNA levels between cells expressing only p65 shRNA and those expressing both shRNA and 
RNAi resistant wild-type or mutant p65 proteins.  When wild-type p65 was over-expressed, we 
observed ~13-fold induction of LTB and ~36-fold induction of TNF (Figure 2.6C, D).  
Expression of the p65 T308A or p65 S311A mutants did not significantly alter the induction of 
LTB and TNF as compared to wild-type p65, but  p65 S356A was roughly half as potent (in all 
cases we determined that wild-type and mutated p65 proteins were expressed at similar levels as 
judged by Western blotting and RT-PCR). The effects of the S356A mutation were gene-specific 
because the levels of the IκBα gene were indistinguishable in the presence of re-expressed wild-
type and mutant p65 (Figure 2.6E). Next we asked whether mutating S356 to aspartic acid to 
mimic the effects of protein phosphorylation would activate p65.  We observed that LTB and 
TNF mRNAs were twice as abundant in cells expressing p65-S356D as compared to wild type 
p65 when expression levels for the two proteins were similar (Figure 2.6F, G). From these data 
we conclude that the most important site of p65 modification by STK38/38L is S356 and the 
phospho-S356 p65 is more active on a subset of NF-κB regulated genes 
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Figure 2.6  Re-expression of wild-type p65 and p65 mutants in p65 knockdown cells. (A) 
Western blots of p65 and GAPDH levels in NS KD, p65 KD cells and p65 KD cells re-
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expressing wild-type p65 or p65 containing various phosphorylation site mutations. (+) denotes 
p65 KD conditions (expression of p65 shRNA). NS denotes expression of non-specifics shRNA. 
All samples were run on the same gel but cut from different lanes. (B) Quantification of proteins 
level in experiments described in (A); the level of p65 in NS KD was normalized to 1. (+) 
denotes p65 shRNA. Error bars represent the standard deviation of the mean of biological 
duplicates. (C, D, E, F, G) Phenotypes associated with expression of WT p65 or p65 carrying 
phosphorylation site mutations (T308A, S311A, S356A and S356D) in p65 KD cells (refer to 
Materials and Methods for experimental details).  Fold induction was calculated based on the 
difference in the number of real-time PCR cycles between p65 re-expressed and p65 KD cells.  
Because ectopic p65 expression causes induction of gene expression, TNFα was not added. Error 
bars represent the standard deviation of the mean of biological duplicates. 
 
2.2.5  Efficient binding of p65 to target genes requires STK38/38L  
 To determine whether STK38/38L is involved in the binding of p65 to the LTB and TNF 
genes we performed chromatin immunoprecipitation (ChIP) experiments. Cells were exposed to 
1% formaldehyde for 10 minutes to crosslink DNA binding proteins to chromatin, complexes 
containing p65 were isolated by immunoprecipitation and levels of promoter binding measured 
by qPCR. For this assay, PCR primers were selected that amplified known κB sequences located 
within1 kb of the start of transcription for each gene.  The amount of p65 binding was quantified 
as the fold change in qPCR signal between cells treated with or without TNF-α for 90 minutes.  
In STK38/38L double knockdown cells, we observed a 2-fold reduction in p65 binding to LTB 
and TNF as compared to control cells, whereas p65 binding to the IκB promoter was not affected 
(Figure 2.7). We conclude that STK38/38L is required for efficient binding of p65 to the 
promoters of target genes, a form of regulation that has described for other phosphorylation 
events on NF-κB subunits (Mosialos and Gilmore, 1993). 
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Figure 2.7  Chromatin immunoprecipitation (ChIP) of p65. Binding of p65 to a κB element 
in the LTB, TNF or IκBα promter in cells treated with exogenous TNF-α. Fold-change in 
binding was quantified from real-time PCR data and represents the difference in samples from 
TNF-treated and untreated cells. Error bars represent the standard deviation of four biological 
replicates. 
 
2.3   DISCUSSION 
 In this paper we use affinity purification and mass spectrometry to identify proteins that 
interact with human p65/RELA, one of the most abundant components of the NF-κB 
transcription factor.  We recovered many established p65-binding proteins and also four proteins 
not previously known to associate with NF-κB. Follow-on co-immunoprecipitation experiments 
confirmed the interaction (direct or indirect) of the serine/threonine kinases STK38 and its close 
homologue STK38L with p65.  STK38 and STK38L, also known as NDR1 and NDR2, are 
highly conserved in yeast, worms, flies, mice and humans (Hergovich et al., 2006) where they 
play a role in a variety of cellular processes, including mitotic exit, cytokinesis, centrosome 
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duplication, cell proliferation and apoptosis (Hergovich et al., 2008). We find that shRNA-
mediated knockdown of both STK38 and STK38L (whose activities could not be distinguished) 
reduces NF-κB –mediated transactivation of TNF-α-responsive genes such as LTB and TNF as 
well as binding of p65 to LTB and TNF promoters.  The product of the TNF gene is the TNF-α 
cytokine itself, which is well known to be regulated in an autocrine manner and involved in 
many important cellular processes (Balkwill, 2006). LTB is a membrane-bound receptor whose 
over-expression causes hepatitis and hepatocellular carcinoma in mice (Balkwill, 2006; 
Haybaeck et al., 2009).  STK38/38L kinases are likely to regulate transcription factors other than 
p65: microarray analysis shows that additional genes are affected by STK38/38L double 
knockdown but not by p65 knockdown. This is consistent with a suggestion from Wang et al 
(Wang et al., 2009) that STK38 is a pleiotropic transcriptional regulator in B cells. However, not 
all p65-regulated genes are regulated by STK38/38L. IκBα, for example, is activated in a p65-
dependent manner by TNFα but it is not affected by STK38/38L knockdown. 
 Not much is known about the substrates of STK38 and STK38L in mammalian cells. We 
find that p65 is an STK38/38L substrate in vitro and that phosphorylation occurs on residues 
T308, S311 and S356. Substituting alanine at any one of these p65 residues reduces 
phosphorylation by STK38/38L by ~50%, but double mutants (e.g. p65-S311A/ S356A) have 
similar effects to single mutants.  This implies a pattern of multi-site phosphorylation in which 
mutation of preferred phosphorylation sites causes other residues become modified, a fairly 
common phenomenon with kinases that bind avidly to their substrates (e.g. (Jeffery et al., 2001)).   
Our ability to dissect STK38/38L phenotypes is negatively impacted by challenges of 
retaining selectivity in shRNA knockdown phenotypes of pro-inflammatory signaling molecules. 
We have explored a wide range of knockdown conditions, testing in each case whether observed 
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phenotypes could be rescued by ectopic expression of an RNAi-resistant wild-type gene. We 
observe that as STK38/38L knockdown phenotypes become stronger (with greater duration of 
shRNA expression) rescue becomes less effective, suggesting a problem with RNAi specificity.  
Anecdotally we have found this problem to be more severe with STK38/38L than with unrelated 
regulatory processes, perhaps reflecting strong feedback regulation in the NF-κB pathway. From 
a practical perspective, further analysis is likely to require cells in which STK38/38L activity can 
be inactivated by a means other than shRNA. Creating knock-in cells that expressed active-site 
STK38/38L mutants that can be acutely inhibited by 1-NAPP1 (using methods developed by 
Shokat and colleagues (Blethrow et al., 2004)), would be one way forward. 
Despite the experimental challenges, four pieces of data argue that STK38/38L is a NF-
κB regulator: (i) STK38/38L binds to p65 and phosphorylates it in vitro  (ii)  STK38/38L 
knockdown cells are less efficient at transactivation of TNF and LTB genes and this defect is not 
rescued by kinase-dead STK38/38L variants (iii) phosphorylation of p65 at S356 site is 
necessary for full LTB and TNF induction and the kinase activity of STK38/38L is required for 
efficient binding of p65 to promoters (iv) a phospho-mimetic alanine to aspartate mutation, p65-
S356D, increases transcription of LTB and TNF above wild type levels. A model of STK38’s 
role in p65-dependent inflammatory gene activation is proposed in Figure 2.8.  
Despite above evidence, we have not conclusively proven that STK38/38L modification 
of p65 is the key regulatory event in vivo.  p65 is known to be modified by many kinases 
(modification of S311 by PKCζ activates p65 for example (Duran et al., 2003)) and given this 
complexity it is difficult to establish unambiguous cause-effect relationships between specific 
kinases and transcriptional activity.  However, no other kinase has previously been reported to 
modify p65-S356 nor has the residue been shown to play a role in NF-κB transcription.  Thus, 
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we believe the most likely hypothesis to be that STK38/38L are p65 co-factors that function by 
modifying p65-S356 and increasing DNA binding activity. 
 
 
Figure 2.8  A proposed model of STK38’s role in p65-dependent inflammatory gene 
activation. In unstimulated conditions, STK38 binds an NF-κB complex containing p65. This 
complex is sequestered in the cytoplasm due to its association with an IκB or IκB-equivalent 
protein. Upon TNF stimulation, IκB is degraded by the 26S proteosome, which allows NF-κB to 
enter the nucleus. Also, with the degradation of IκB, serine 356 of p65 is phosphorylated by 
STK38, which facilitates recruitment of transcriptional co-activators at selected NF-κB gene 
promoters and resulting in enhancement of gene transcription.    
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2.4   MATERIALS AND METHODS  
Cell lines and Reagents  
Human colorectal carcinoma HCT116 cells were cultured in McCoy5A media plus 10% 
FBS and 1% penicillin/streptomycin. HEK 293T cells were cultured in DMEM with the same 
supplements as HCT116. The following antibodies were used: anti-p65 (sc-109, sc-372 from 
Santa-Cruz); anti-GAPDH (from Abcam); anti-STK38 (from Abnova); anti-STK38L (gift from 
Dr. Hemmings, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland); anti-
Streptag II (from Qiagen). Other reagents were purchased from the following vendors: TNF-α 
from PeproTech; SYBR reaction mix from Applied Biosystems; TurboFect in vitro transfection 
reagent from Fermentas; anti-FLAG and anti-HA resin from Sigma., Production of adeno-
associated viruses and screening for resistant clones carrying the knock-in construct were done 
according to protocol from the Vogelstein and Bunz laboratories (Rago et al., 2007). Once, a 
knock-in clone was identified, the selection cassette was removed using Ad-Cre (adeno viruses 
expressing Cre-recombinase) to ensure proper expression of the knock-in protein. 
Plasmid Constructs 
The AAV p65 knock-in construct was generated by fusing the left homology arm (LHA), 
SEPT fragment containing a neo selection gene (from pSEPT vector, gift from the Bunz 
laboratory, Johns Hopkins University School of Medicine, Maryland, USA) and the right 
homology arm (RHA) by PCR. The LHA and RHA are about 1kb in length and contain the NotI 
restriction sites at the outer left of the LHA and outer right of the RHA. The fusion PCR product 
was cloned into the NotI sites of pAAV-MCS. Plasmids expressing candidate p65 interactors 
were constructed using the following restriction sites: BamHI and SalI for STK38, CCT6A, 
PRMT1, SERBP1; BamHI and EcoRI for STK38L. Fragments were cloned into the pNTAP-C 
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vector (Stratagene) containing the tandem affinity Streptavidin and Calmodulin-binding peptide 
tag at the N terminus. Also, a StrepTag II sequence (Qiagen) was included for Western blot 
detection. After being cloned into the pNTAP-C vector, the following genes, STK38 (cut with 
BglII and SacII), STK38L (cut with EcoRI and SacII), CCT6A (cut with BglII and SacII), 
SERBP1 (cut with NheI and EcoRI) were inserted into pEGFP-N1 vector. This serves two 
purposes, the first for separating them from the p65 band on Western blots and the second for 
visualization of protein expression. The p65 expression vector was made by adding an HA tag 
sequence at the beginning of the gene and inserting it in the pEGFP-N1 with p65’s stop codon 
included. All cDNAs for cloning were generated by RT-PCR from the mRNA extract of 
HCT116 cells. Point mutations introduced into STK38 (K118A), STK38L (K119A), p65 
(T308A, S311A, S356A, S311A S356A, S356D) were created using the site-directed mutagensis 
kit from Strategene.  pAAV-MCS, pHelper and pRC vectors were gifts from the Lois laboratory, 
Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, 
Cambridge, USA. 
Liquid chromatography/Mass Spectrometry (LC/MS) Analysis 
Each MS sample was prepared from 5x108 cells. Cells were lysed using lysate buffer 
(0.1% NP-40 in 25 mM HEPES pH 7.5, 10% glycerol supplemented with protease inhibitors 
leupeptin, pepstatin, chymostatin and phosphatase inhibitors sodium orthovanadate, sodium 
fluoride, and beta-glycerol phosphate). Affinity purification was carried out using anti-FLAG 
resin.  Bound protein complexes were eluted using 0.1 M glycine HCl, pH 3.5. Proteins were 
precipitated by adding TCA (6%) and sodium deoxycholate (0.02%), samples were placed on ice 
for 1 hour then centrifuged, pellets were washed with ice-cold acetone and resuspended in 10% 
acetonitrile in 50 mM sodium bicarbonate solution. Four different samples representing parental 
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cells treated with and without 100 ng/mL TNF-α and knocked-in p65-tagged HCT116 cells with 
and without TNF-α were submitted for MS analysis on the LTQ-FT machine from Thermo 
Electron. For phospho-MS analysis of p65 sites, an in vitro kinase was carried out using ATP 
followed by SDS-PAGE. The gel was stained with Colloidal Blue (Invitrogen) and the band 
corresponding to p65 was excised and submitted for phospho-mass spectrometry using the LTQ-
FT machine from Thermo Electron. To maximize the number of phospho peptides identified, 
each sample was digested with either trypsin alone or trypsin/chymotrypsin together. All mass 
spectrometry analyses were performed in the Taplin mass spectrometry facility at the Harvard 
Medical School.  
Reciprocal immunoprecipitation 
Candidate proteins and p65 were expressed separately in HEK 293T cells by transient 
transfection. 24-hour post-transfection, cell lysates were collected. To measure the binding of 
each candidate protein to p65, lysates from cells expressing a tagged version of each protein 
were mixed with lysate from HEK 293T cells over-expressing p65, or in the case of data shown 
in Figure 2.2C and D with lysates from HCT116 cells expressing p65 at endogenous levels. 
Mixtures were rotated overnight at 4oC with Strep-Tactin Superflow Plus (Qiagen) resin to pull 
down the tagged proteins followed by analysis on SDS-PAGE gels; anti-p65 antibodies were 
used to measure the extent of binding to p65 by Western blotting.  
Gene expression profiling and data analysis 
 mRNA samples were prepared by using the NucleoSpin RNA II kit (Macherey-Nagel). 
cDNA was synthesized and labeled before hybridizing on the Affymatrix Human U133A 2.0 
chips according to manufacturer’s protocol. Biological duplicates were prepared for each 
condition. Expression data were normalized using quantile normalization. Genes were 
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considered to be affected if either p65 or STK38/38L knockdown cells exhibited decreased 
expression by >1.8-fold compared to non-specific knockdown cells when treated with 100 
ng/mL TNF-α for 6 hours. To select for genes whose expressions were dependent on TNF-α 
treatment, a >1.8-fold increase cut-off was chosen when comparing expression data between 
untreated and treated samples. Microarray data collection was performed at the BioMicro Center 
at the Massachusetts Institute of Technology. 
Quantitative real-time PCR and Chromatin Immunopreciptation Assays 
 mRNA samples were extracted from cells using the NucleoSpin RNA II kit (Macherey-
Nagel). cDNA synthesis was done using RETROscript kit with oligo (dT) (Applied Biosystems). 
qPCR reactions were performed in duplicate by using SYBR Green PCR Master Mix (Applied 
Biosystems) in the Eppendorf  Realplex Mastercycler S machine.  Primers are listed in 
supplementary Table S-2.7. The relative transcription level was calculated by using the ΔΔCt 
method with GAPDH as a normalization control. 
 For Chromatin Immunopreciptation (ChIP) assays, cells were treated with TNF-α for 90 
minutes followed by fixation with 10% formaldehyde (1% final concentration) for 10 minutes. 
Cells were lysed first in swelling buffer for 15 minutes (25mM HEPES pH 7.8, 1.5 mM MgCl2, 
10mM KCl, 0.1% NP-40, 1mM DTT, protease inhibitors (leupeptin, pepstatin, chymostatin) then 
in sonication buffer (50mM HEPES pH 7.8, 140mM NaCl, 1mM EDTA, 0.1% SDS, 1% 
TritonX-100 supplemented with protease inhibitors (leupeptin, pepstatin, chymostatin). Samples 
were sonicated for 3 minutes with 20-second pulse intervals and 1 minute off at each interval at 
4oC using a Fisher-Scientific 550 Sonic Dismembrator with output setting at 3.5. Chromatin was 
immunoprecipitated using an anti-p65 (sc-372 Ab from Santa-Cruz) and Dynabead Protein A 
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(Invitrogen) at 4oC overnight. DNA was purified using phenol/chloroform precipitation method. 
Real-time PCR was used to quantify promoter’s binding.  
In vitro kinase assays 
Both kinases and substrates were generated by transient transfection of tagged proteins in 
HEK 293T cells using TurboFect in vitro transfection reagent (Fermentas). Kinases were 
purified using Strep-Tactin Superflow Plus resin (eluted with d-desthiobiotin; Sigma) and 
substrates were purified using anti-HA resin (eluted with HA peptide; Sigma). Kinases were first 
incubated with 1x kinase buffer (25 mM HEPES pH 7.5, 5 mM β-glycerophosphate, 2 mM 
dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2, 2 μM unlabelled ATP) for 15 minutes at room 
temperature to allow for their activation. Substrates were then added together with 5 μCi of [γ-
32P]ATP in a 50 μl reaction volume. Reactions were stopped using SDS sample buffer after 50 
minutes at room temperature. Proteins were resolved by 8% SDS–PAGE, gels were dried and 32P 
incorporation was measured by autoradiography.  
shRNA knockdown cells  
Doxycyclin (Dox)-inducible shRNA lentivirus-based vectors for STK38, p65 and non 
specific (NS) targets and non-inducible vectors for STK38L were purchased from Open 
Biosystems. Viruses were made using HEK 293T according to manufacturer’s protocol using 
helper plasmids pCGgag/pol, and pVSV-G (gifts from the Elledge laboratory, Harvard Medical 
School, Boston, USA). Knock-in HCT116 cells were infected using 4-8 μg/ml polybrene. 
Viruses were removed after 24 h. Cells were then selected with puromycin (0.5-2μg/ml) to 
remove uninfected population. To make STK38/STK38L double knockdown cells, STK38 single 
knockdown cells were generated first and these cells were used for a second round of infection 
with viruses carrying the STK38L shRNA vector. Since the shRNA vector for STK38L 
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expresses a GFP reporter, sorting was used to select for cells that were successfully infected with 
the STK38L shRNA vector. 
 To determine if phenotypes associated with shRNA expression could be rescued by 
expression of wild-type or mutated genes, shRNA-expressing  cells were treated with Dox for 72 
hours to knock down target genes. The knockdown genes were rescued by transiently 
transfecting vectors carrying these genes. The shRNA against STK38 is toward the 3’UTR, so 
rescuing with STK38 cDNAs require no further modifications. However, for p65 rescue, silent 
mutations were introduced into the region of plasmids carrying p65 cDNAs where p65’s shRNA 
recognizes by site directed mutagenesis.  Approximately, four hours post-transfection, media was 
changed to a 2% serum media plus Dox. Cells were allowed to grow for four more days prior to 
TNF-α stimulation (STK38 rescue) followed by mRNA extractions and real-time PCR.    
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2.6   SUPPLEMENTAL INFORMATION 
 
 
 
 
Figure S-2.1  In vitro kinase assay.  Kinases and p65 substrate were expressed in 293T cells. 
Cells expressing kinases were treated with 100 ng/mL TNF-α or IGF for 6 hours before lysates 
were collected. After affinity purification, proteins were run on SDS-PAGE gel and stained with 
Coomassie blue to estimate their relative levels. In-vitro kinase assay was performed in which 
the amount of substrate added was at least twice that of kinase. Purified STK38 and STK38L 
from untreated or TNF-α or IGF treated cells can phosphorylate p65 and there appears to be no 
significant difference in p65’s phosphorylation signal between these conditions.  
 
 
 
 
 
 
 
 
 
 
79 
 
Table-S-2.1 p65 binding partners. Lysate samples from HCT116 cells carrying a p65 
expressing a FLAG tag were run through an anti-FLAG resin column. Eluted fractions 
containing p65 interacting proteins were analysed by mass spectrometry. Candidate p65 
interactors were selected if they were reproducibly identified in two independent experiments 
and were represented by at least two different peptides.  
 
Gene symbol Gene name 
ANM5 Protein arginine n-methyltransferase 5 
HSP7C Heat shock cognate 71 kda protein  
GRP78 78 kda glucose-regulated protein precursor  
TF65 Nuclear factor nf-kappa-b p65 subunit 
GRP75 75 kda glucose-regulated protein 
STK38 Serine/threonine-protein kinase 38  
ST38L Serine/threonine-protein kinase 38-like  
NFKB1 Nuclear factor nf-kappa-b p105 subunit  
ATPB ATP synthase subunit beta 
HS70L Heat shock 70 kda protein 1-like 
ANM1 Protein arginine n-methyltransferase 1 
HS90A Heat shock protein hsp 90-alpha  
TBA2 Tubulin alpha-2 chain  
RSSA 40s ribosomal protein sa  
IKBE NF-kappaB inhibitor epsilon  
HSP72 Heat shock-related 70 kda protein 2 
ANXA1 Annexin a1  
G3P Glyceraldehyde-3-phosphate dehydrogenase  
EZRI Ezrin  
HSP71 Heat shock 70 kda protein 1 
PAIRB Serpine1 mrna-binding protein 1 
CDK9 Cell division protein kinase 9 
NFKB2 Nuclear factor nf-kappa-b p100 subunit  
TBB1 Tubulin beta-1 chain 
ATPA ATP synthase subunit alpha 
IKBA NF-kappaB inhibitor alpha 
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REL c-Rel protein 
IKBB NF-kappaB inhibitor beta 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 
Table-S-2.2 Genes upregulated by TNF-α stimulation. NS KD HCT116 cells were treated 
with 100 ng/mL TNF-α or mock control for 6 hours before mRNA samples were collected. 
cDNA was synthesized and labeled before hybridizing on the Affymatrix Human U133A 2.0 
chips according to manufacturer’s protocol. Biological duplicates were prepared for each 
condition. GC-RMA method was used to extract the gene expression values. Expression data 
were then normalized using quantile normalization. To select for genes whose expressions were 
dependent on TNF-α treatment, a >1.8-fold increase cut-off was chosen when comparing 
expression data between untreated and treated samples. 
 
 
Gene symbol Gene name 
BIRC3 baculoviral IAP repeat-containing 3 
IL8 interleukin 8 
CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 
APOL6 apolipoprotein L, 6 
APOL3 apolipoprotein L, 3 
UBD ubiquitin D 
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 
TNFRSF9 tumor necrosis factor receptor superfamily, member 9 
PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional peptidase 2) 
CXCL2 chemokine (C-X-C motif) ligand 2 
IFI44 interferon-induced protein 44 
TNFAIP2 tumor necrosis factor, alpha-induced protein 2 
SAA1, SAA2 serum amyloid A1, serum amyloid A2 
ICAM1 intercellular adhesion molecule 1 
IFIH1 interferon induced with helicase C domain 1 
TLR3 toll-like receptor 3 
CCL20 chemokine (C-C motif) ligand 20 
UBE2L6 ubiquitin-conjugating enzyme E2L 6 
TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 
ISG20 interferon stimulated exonuclease gene 20kDa 
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 
CD83 CD83 molecule 
IFIT3 interferon-induced protein with tetratricopeptide repeats 3 
LTB lymphotoxin beta (TNF superfamily, member 3) 
STAT1 signal transducer and activator of transcription 1, 91kDa 
NMI N-myc (and STAT) interactor 
TYMP thymidine phosphorylase 
IRF1 interferon regulatory factor 1 
IL15 interleukin 15 
LAMP3 lysosomal-associated membrane protein 3 
DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 
OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 
BTN3A1 butyrophilin, subfamily 3, member A1 
IFI35 interferon-induced protein 35 
ERAP1 endoplasmic reticulum aminopeptidase 1 
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HCP5 HLA complex P5 
SAMD9 sterile alpha motif domain containing 9 
IFI6 interferon, alpha-inducible protein 6 
GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 
USP18 ubiquitin specific peptidase 18 
OPTN optineurin 
TNIP1 TNFAIP3 interacting protein 1 
ZC3HAV1 zinc finger CCCH-type, antiviral 1 
BST2 bone marrow stromal cell antigen 2 
NAV3 neuron navigator 3 
SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin), member 1 
B2M beta-2-microglobulin 
APOL2 apolipoprotein L, 2 
CYLD cylindromatosis (turban tumor syndrome) 
CASP4 caspase 4, apoptosis-related cysteine peptidase 
NFKB2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) 
LRRC49 leucine rich repeat containing 49 
MUC1 mucin 1, cell surface associated 
SP110 SP110 nuclear body protein 
RASGRP3 RAS guanyl releasing protein 3 (calcium and DAG-regulated) 
DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 
SERPINB9 serpin peptidase inhibitor, clade B (ovalbumin), member 9 
CXCL11 chemokine (C-X-C motif) ligand 11 
ISG15 ISG15 ubiquitin-like modifier 
SECTM1 secreted and transmembrane 1 
NAV2 neuron navigator 2 
PPARD peroxisome proliferator-activated receptor delta 
PLAU plasminogen activator, urokinase 
HDAC9 histone deacetylase 9 
APOL1 apolipoprotein L, 1 
SP100 SP100 nuclear antigen 
HLA-F major histocompatibility complex, class I, F 
SYNGR3 synaptogyrin 3 
IFIT5 interferon-induced protein with tetratricopeptide repeats 5 
RARRES3 retinoic acid receptor responder (tazarotene induced) 3 
CXCL3 chemokine (C-X-C motif) ligand 3 
ZBED2 zinc finger, BED-type containing 2 
DAPP1 dual adaptor of phosphotyrosine and 3-phosphoinositides 
BTN3A3 butyrophilin, subfamily 3, member A3 
JUN jun oncogene 
CD40 CD40 molecule, TNF receptor superfamily member 5 
IFIT2 interferon-induced protein with tetratricopeptide repeats 2 
NFE2L3 nuclear factor (erythroid-derived 2)-like 3 
BTN2A2 butyrophilin, subfamily 2, member A2 
ETV7 ets variant 7 
IFIT1 interferon-induced protein with tetratricopeptide repeats 1 
SLC12A7 solute carrier family 12 (potassium/chloride transporters), member 7 
CFLAR CASP8 and FADD-like apoptosis regulator 
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CCL5 chemokine (C-C motif) ligand 5 
SRCAP Snf2-related CREBBP activator protein 
HLA-B major histocompatibility complex, class I, B 
DRAM damage-regulated autophagy modulator 
EHD1 EH-domain containing 1 
FAS Fas (TNF receptor superfamily, member 6) 
ITGB8 integrin, beta 8 
IFNGR2 interferon gamma receptor 2 (interferon gamma transducer 1) 
BCL3 B-cell CLL/lymphoma 3 
TAPBP TAP binding protein (tapasin) 
HIVEP1 human immunodeficiency virus type I enhancer binding protein 1 
ACSL5 acyl-CoA synthetase long-chain family member 5 
LHFP lipoma HMGIC fusion partner 
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 
SAMD4A sterile alpha motif domain containing 4A 
PLCB4 phospholipase C, beta 4 
HIVEP2 human immunodeficiency virus type I enhancer binding protein 2 
ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 
CLIC5 chloride intracellular channel 5 
TAP2 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 
ATF3 activating transcription factor 3 
CXCR4 chemokine (C-X-C motif) receptor 4 
IL15RA interleukin 15 receptor, alpha 
CLEC2B C-type lectin domain family 2, member B 
BIRC2 baculoviral IAP repeat-containing 2 
SOD2 superoxide dismutase 2, mitochondrial 
HLA-E major histocompatibility complex, class I, E 
BTG1 B-cell translocation gene 1, anti-proliferative 
RC3H2 ring finger and CCCH-type zinc finger domains 2 
NRIP1 nuclear receptor interacting protein 1 
MALT1 mucosa associated lymphoid tissue lymphoma translocation gene 1 
ZNF695 zinc finger protein 695 
TRIM21 tripartite motif-containing 21 
SEC23B Sec23 homolog B (S. cerevisiae) 
EFNA1 ephrin-A1 
BTN3A2 butyrophilin, subfamily 3, member A2 
CES2 carboxylesterase 2 (intestine, liver) 
PLSCR1 phospholipid scramblase 1 
BCL6 B-cell CLL/lymphoma 6 
GBP2 guanylate binding protein 2, interferon-inducible 
NRG1 neuregulin 1 
PTGES prostaglandin E synthase 
DUSP10 dual specificity phosphatase 10 
ZC3H7B zinc finger CCCH-type containing 7B 
OASL 2'-5'-oligoadenylate synthetase-like 
MUC3B mucin 3B, cell surface associated 
IRF9 interferon regulatory factor 9 
ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 
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WWC1 WW and C2 domain containing 1 
HLA-C major histocompatibility complex, class I, C 
PDE4DIP phosphodiesterase 4D interacting protein 
IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor) 
PLAUR plasminogen activator, urokinase receptor 
PSME2 proteasome (prosome, macropain) activator subunit 2 (PA28 beta) 
MMD monocyte to macrophage differentiation-associated 
OBFC2A oligonucleotide/oligosaccharide-binding fold containing 2A 
PISD phosphatidylserine decarboxylase 
DNPEP aspartyl aminopeptidase 
ZNF160 zinc finger protein 160 
CD47 CD47 molecule 
PARP8 poly (ADP-ribose) polymerase family, member 8 
CD44 CD44 molecule (Indian blood group) 
JUNB jun B proto-oncogene 
RELB v-rel reticuloendotheliosis viral oncogene homolog B 
REL v-rel reticuloendotheliosis viral oncogene homolog (avian) 
SLC35E1 solute carrier family 35, member E1 
SDC4 syndecan 4 
FGD6 FYVE, RhoGEF and PH domain containing 6 
EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 
RPS17L4 ribosomal protein S17-like 4 
DGKE diacylglycerol kinase, epsilon 64kDa 
ELL2 elongation factor, RNA polymerase II, 2 
PHF11 PHD finger protein 11 
ASMTL acetylserotonin O-methyltransferase-like 
PLK2 polo-like kinase 2 (Drosophila) 
IRS2 insulin receptor substrate 2 
NBN nibrin 
IFNAR2 interferon (alpha, beta and omega) receptor 2 
RAB7A RAB7A, member RAS oncogene family 
IDS iduronate 2-sulfatase 
KTN1 kinectin 1 (kinesin receptor) 
IRF2 interferon regulatory factor 2 
C3 complement component 3 
HSPG2 heparan sulfate proteoglycan 2 
STYK1 serine/threonine/tyrosine kinase 1 
LIPG lipase, endothelial 
ERAP2 endoplasmic reticulum aminopeptidase 2 
MYD88 myeloid differentiation primary response gene (88) 
ITM2B integral membrane protein 2B 
ZFP36L1 zinc finger protein 36, C3H type-like 1 
ITPKC inositol 1,4,5-trisphosphate 3-kinase C 
OTUD4 OTU domain containing 4 
CHMP5 chromatin modifying protein 5 
CYR61 cysteine-rich, angiogenic inducer, 61 
TANK TRAF family member-associated NFKB activator 
VAMP1 vesicle-associated membrane protein 1 (synaptobrevin 1) 
85 
 
KLF9 Kruppel-like factor 9 
SAT1 spermidine/spermine N1-acetyltransferase 1 
SAMHD1 SAM domain and HD domain 1 
SEMA3C sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C 
SMG1 SMG1 homolog, phosphatidylinositol 3-kinase-related kinase (C. elegans) 
TRAF3 TNF receptor-associated factor 3 
AGPAT4 1-acylglycerol-3-phosphate O-acyltransferase 4 (lysophosphatidic acid acyltransferase, delta) 
DSE dermatan sulfate epimerase 
HGSNAT heparan-alpha-glucosaminide N-acetyltransferase 
GRAMD3 GRAM domain containing 3 
GALNT6 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 
MAOA monoamine oxidase A 
ATP8B1 ATPase, class I, type 8B, member 1 
FGF2 fibroblast growth factor 2 (basic) 
ELK3 ELK3, ETS-domain protein (SRF accessory protein 2) 
ZNF136 zinc finger protein 136 
GCH1 GTP cyclohydrolase 1 
APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B 
SMAD3 SMAD family member 3 
PDE4C phosphodiesterase 4C, cAMP-specific (phosphodiesterase E1 dunce homolog, Drosophila) 
PICALM phosphatidylinositol binding clathrin assembly protein 
HEG1 HEG homolog 1 (zebrafish) 
TICAM1 toll-like receptor adaptor molecule 1 
NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
SLC25A22 solute carrier family 25 (mitochondrial carrier: glutamate), member 22 
UGCG UDP-glucose ceramide glucosyltransferase 
UBE2H ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) 
TRIM6-TRIM34 tripartite motif-containing 34 - tripartite motif-containing 6 
PSMB10 proteasome (prosome, macropain) subunit, beta type, 10 
EIF2AK3 eukaryotic translation initiation factor 2-alpha kinase 3 
BAZ1A bromodomain adjacent to zinc finger domain, 1A 
STC2 stanniocalcin 2 
YOD1 YOD1 OTU deubiquinating enzyme 1 homolog (S. cerevisiae) 
MICB MHC class I polypeptide-related sequence B 
RPL35A Ribosomal protein L35a 
PARP12 poly (ADP-ribose) polymerase family, member 12 
NKX3-1 NK3 homeobox 1 
IL4R interleukin 4 receptor 
MSN moesin 
MAFF v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) 
SGMS1 sphingomyelin synthase 1 
GLS glutaminase 
PSMB2 proteasome (prosome, macropain) subunit, beta type, 2 
LRCH3 leucine-rich repeats and calponin homology (CH) domain containing 3 
MFHAS1 malignant fibrous histiocytoma amplified sequence 1 
JMJD3 jumonji domain containing 3, histone lysine demethylase 
CASP8 caspase 8, apoptosis-related cysteine peptidase 
COPA coatomer protein complex, subunit alpha 
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TNFAIP1 tumor necrosis factor, alpha-induced protein 1 (endothelial) 
SIPA1L3 signal-induced proliferation-associated 1 like 3 
TOR1AIP1 torsin A interacting protein 1 
ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 
IGSF3 immunoglobulin superfamily, member 3 
TDRD7 tudor domain containing 7 
ABI1 abl-interactor 1 
SPATA2L spermatogenesis associated 2-like 
FBXO38 F-box protein 38 
CCRN4L CCR4 carbon catabolite repression 4-like (S. cerevisiae) 
ROD1 ROD1 regulator of differentiation 1 (S. pombe) 
RAB27A RAB27A, member RAS oncogene family 
TNF Tumor necrosis factor alpha  
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Table-S-2.3 Genes downregulated by p65 knockdown. NS KD and p65 KD HCT116 cells 
were treated with 100 ng/mL TNF-α for 6 hours before mRNA samples were collected. cDNA 
was synthesized and labeled before hybridizing on the Affymatrix Human U133A 2.0 chips 
according to manufacturer’s protocol. Biological duplicates were prepared for each condition. 
GC-RMA method was used to extract the gene expression values. Expression data were then 
normalized using quantile normalization. To select for genes whose expressions were 
downregulated by p65 knockdown, a >1.8-fold decrease cut-off was chosen when comparing 
expression data between ND KD and p65 KD samples. 
 
Gene symbol Gene name 
 PLCB4 phospholipase C beta 4 
 TNFAIP3 tumor necrosis factor alpha-induced protein 3 
 IKBKB inhibitor of kappa light polypeptide gene enhancer in B-cells kinase beta 
 PTGES prostaglandin E synthase 
 BIRC3 baculoviral IAP repeat-containing 3 
 SPG11 spastic paraplegia 11 (autosomal recessive) 
 TYMP thymidine phosphorylase 
 BTN3A1 butyrophilin subfamily 3 member A1 
 LMO2 LIM domain only 2 (rhombotin-like 1) 
 CIR CBF1 interacting corepressor 
 HERC5 hect domain and RLD 5 
 CCNG2 cyclin G2 
 SERPINB9 serpin peptidase inhibitor clade B (ovalbumin) member 9 
 ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 
 IFNGR1 interferon gamma receptor 1 
 TRIM38 tripartite motif-containing 38 
 EFNA1 ephrin-A1 
 CD83 CD83 molecule 
 IFI6 interferon alpha-inducible protein 6 
 IFIH1 interferon induced with helicase C domain 1 
 BTN2A2 butyrophilin subfamily 2 member A2 
 TNFAIP2 tumor necrosis factor alpha-induced protein 2 
 CXCL3 chemokine (C-X-C motif) ligand 3 
 ICAM1 intercellular adhesion molecule 1 (CD54) human rhinovirus receptor 
 ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 
 ITGB8 integrin beta 8 
 S100PBP S100P binding protein 
 TPPP tubulin polymerization promoting protein 
 SLC25A15 solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15 
 IFNAR2 interferon (alpha beta and omega) receptor 2 
 LIMK2 LIM domain kinase 2 
 IL17RB interleukin 17 receptor B 
 DGKE diacylglycerol kinase epsilon 64kDa 
 ADD3 adducin 3 (gamma) 
 MAP3K5 mitogen-activated protein kinase kinase kinase 5 
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 IFNGR1 interferon gamma receptor 1 
 OS9 amplified in osteosarcoma 
 ALCAM activated leukocyte cell adhesion molecule 
 PCDH1 protocadherin 1 
 SOD2 superoxide dismutase 2 mitochondrial 
 PLCB4 phospholipase C beta 4 
 EGFR epidermal growth factor receptor 
 SP110 SP110 nuclear body protein 
 TNF tumor necrosis factor alpha 
 NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha 
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Table-S-2.4 Genes downregulated by STK38/38L knockdown. NS KD and STK38/38L KD 
HCT116 cells were treated with 100 ng/mL TNF-α for 6 hours before mRNA samples were 
collected. cDNA was synthesized and labeled before hybridizing on the Affymatrix Human 
U133A 2.0 chips according to manufacturer’s protocol. Biological duplicates were prepared for 
each condition. GC-RMA method was used to extract the gene expression values. Expression 
data were then normalized using quantile normalization. To select for genes whose expressions 
were downregulated by p65 knockdown, a >1.7-fold decrease cut-off was chosen when 
comparing expression data between ND KD and STK38/38L KD samples. 
 
Gene symbol Gene name 
 STK38L serine/threonine kinase 38 like 
 STK38 serine/threonine kinase 38 
 TACSTD2 tumor-associated calcium signal transducer 2 
 (SAA1, SAA2) serum amyloid A1, serum amyloid A2 
 INSIG1 insulin induced gene 1 
 FGFBP1 fibroblast growth factor binding protein 1 
 INSIG1 insulin induced gene 1 
 TRIM2 tripartite motif-containing 2 
 STK38 Serine/threonine kinase 38 
 ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 
 HMGCS1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 
 DYRK1A dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A 
 GIT2 G protein-coupled receptor kinase interactor 2 
 TRIM2 tripartite motif-containing 2 
 SCD stearoyl-CoA desaturase 
 FZD7 frizzled homolog 7 
 IL18 interleukin 18 
 LTB lymphotoxin beta 
 TNF tumor necrosis factor alpha 
 GNS glucosamine (N-acetyl)-6-sulfatase 
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Table-S-2.5 Genes upregulated by p65 knockdown. NS KD and p65 KD HCT116 cells were 
treated with 100 ng/mL TNF-α for 6 hours before mRNA samples were collected. cDNA was 
synthesized and labeled before hybridizing on the Affymatrix Human U133A 2.0 chips 
according to manufacturer’s protocol. Biological duplicates were prepared for each condition. 
GC-RMA method was used to extract the gene expression values. Expression data were then 
normalized using quantile normalization. To select for genes whose expressions were 
downregulated by p65 knockdown, a >1.8-fold increase cut-off was chosen when comparing 
expression data between ND KD and p65 KD samples. 
 
Gene symbol Gene name 
 SETD2 SET domain containing 2 
 TSPAN5 tetraspanin 5 
 JUN jun oncogene 
 RNASET2 ribonuclease T2 
 NOL5A nucleolar protein 5A (56kDa with KKE/D repeat) 
 XPO4 exportin 4 
 SART3 squamous cell carcinoma antigen recognized by T cells 3 
 SLC43A3 solute carrier family 43 member 3 
 MAPK1 mitogen-activated protein kinase 1 
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Table-S-2.6 Genes upregulated by STK38/38L knockdown. NS KD and STK38/38L KD 
HCT116 cells were treated with 100 ng/mL TNF-α for 6 hours before mRNA samples were 
collected. cDNA was synthesized and labeled before hybridizing on the Affymatrix Human 
U133A 2.0 chips according to manufacturer’s protocol. Biological duplicates were prepared for 
each condition. GC-RMA method was used to extract the gene expression values. Expression 
data were then normalized using quantile normalization. To select for genes whose expressions 
were downregulated by p65 knockdown, a >1.7-fold increase cut-off was chosen when 
comparing expression data between ND KD and STK38/38L KD samples. 
 
Gene symbol Gene name 
 MYCBP2 MYC binding protein 2 
 ZNF232 zinc finger protein 232 
 VCAN versican 
 ADFP adipose differentiation-related protein 
 BRD4 bromodomain containing 4 
RBP1 retinol binding protein 1  
 FBXO42 F-box protein 42 
 LASS6 LAG1 homolog ceramide synthase 6 
 INTS7 integrator complex subunit 7 
 MSRB2 methionine sulfoxide reductase B2 
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qPCR primers 
Target gene Forward (5’- 3’) Reverse (5’- 3’) 
LTB GACGAAGGAACAGGCGTTTCT GTAGCCGACGAGACAGTAGAG 
TNF CCCAGGGACCTCTCTCTAATCA GCTACAGGCTTGTCACTCGG 
IκBα CCGCACCTCCACTCCATCC ACATCAGCACCCAAGGACACC 
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
 
ChIP primers 
Target 
promoter 
Forward (5’- 3’) Reverse (5’- 3’) 
LTB AGAGCCTGTCTCCCTAACCTC- 
AACTTC 
CCTGTAGACCTGCACACCTGGC 
TNF TCTGGGAATTCCAATCCTTGC- 
TGGGAAA 
TTAAGTGGCTGGTTCAGGTTG- 
CAGAGTT 
IκBα AAGGCTCACTTGCAGAGGGACAGG- 
ATTA 
GGAATTTCCAAGCCAGTCAGA- 
CCAGAAA 
 
Table-S-2.7  Primers for realtime PCR and ChIP (listed in the 5’ to 3’ direction). 
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3.1   INTRODUCTION 
Tumorigenesis is a multi-step process where normal cells have undergone to acquire 
malignancy. Two of the most important events leading up to cancer are genomic instability and 
inflammation (Hanahan and Weinberg, 2011). Genomic instability occurs through the generation 
of random mutations including chromosomal rearrangements and rare genetic changes that allow 
cancer cells to survive, proliferate, and disseminate (Jackson and Bartek, 2009; Negrini et al., 
2010). While genomic instability has been demonstrated as one of enabling characteristics of 
cancer development for some time, inflammation, a process normally activated by our body to 
protect us from harmful stimuli like pathogens, dead cells and irritants, has only been recognized 
to be an important characteristics of tumorigenesis in the past decade or so (DeNardo et al., 
2010; Grivennikov et al., 2010).  
Virtually every tumor has been observed to be surrounded by immune cells (Pages et al., 
2010). Such immune responses were originally thought of as an attempt by the immune system 
to eradicate tumors, which is true in some cases. However, tumor-associated inflammation has 
been shown to have an unanticipated effect of enhancing tumorigenesis and progression. 
Inflammation can cause the release of cytokines to the tumor microenvironment that can 
facilitate proliferation, survival, angiogenesis, invasion, metastasis, and activation of epithelial-
mesenchymal transition (DeNardo et al., 2010; Grivennikov et al., 2010; Qian and Pollard, 
2010). 
Two of the most pleiotropic pro-inflammatory cytokines are TNF-α and IL-1α. TNF-α 
and IL-1α family proteins are abundant at tumor sites and they represent potent molecules that 
may greatly influence the direction of the malignant process (Apte et al., 2006; Balkwill, 2006). 
Although TNF-α and IL-1α bind to different types of receptors which then recruit different 
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adaptor molecules, both TNF-α and IL-1α can activate a common pathway that involves the 
transcription factor NF-κB (Locksley et al., 2001; Weber et al., 2010). This pathway has dual 
actions in tumor promotion: first by preventing death of cells with malignant potential, and 
second by stimulating production of pro-inflammatory cytokines (Varfolomeev and Ashkenazi, 
2004). The survival branch of NF-κB activation involves upregulation of negative regulators of 
apoptosis such as c-FLIP, Bcl-2 while the death branch is mediated through caspase 8 and via 
accumulation of intracellular reactive oxygen, sustained Jun N-terminal kinase activation and 
mitochondrial pathways (Karin and Lin, 2002).  
Given the role of pro-inflammatory cytokines in cancer in general and in apoptosis in 
particular, when it comes to cancer treatment, one important question is how the presence of 
these molecules affects the effectiveness of a therapy. One promising anti-cancer drug is TRAIL 
(TNF-Related Apoptosis Inducing Ligand). TRAIL has attracted considerable attention owing to 
its selective killing of tumor cells while normal cells were largely protected (LeBlanc and 
Ashkenazi, 2003). In animal models, treatment with TRAIL by itself or in combination with 
other drugs resulted in suppression of tumor xenografts without causing systemic toxicity 
(Kelley and Ashkenazi, 2004; Walczak et al., 1999). Clinical trials using TRAIL have been 
reported for patients with non-small-cell lung cancer, non-Hodgkin’s lymphoma and colorectal 
carcinoma (Fischer and Schulze-Osthoff, 2005). Despite its tumor specific killing, some tumors 
can survive TRAIL treatment, which presents a major barrier for the development of efficient 
therapies (Kurbanov et al., 2007; Morizot et al., 2010; Wang and El-Deiry, 2003). Resistance to 
TRAIL has been suggested to be due to increased levels of antiapoptotic proteins such as c-FLIP, 
Bcl-2, Bcl-xL and inhibitors of apoptosis proteins (IAPs) (Zhang and Fang, 2005). As many of 
these proteins are known targets of NF-κB and this transcription factor is activated by pro-
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inflammatory cytokines that are present at tumor’s sites, this suggests that there is a link between 
inflammation and TRAIL resistance. 
In this work, we examined the role of pro-inflammatory cytokines in TRAIL-induced cell 
death. Using a panel of four human liver cell lines, we first asked how pre-treatment of TNF-α 
and IL-1α affects the cell death response by TRAIL. To determine whether the NF-κB pathway 
is responsible for the observed apoptotic outcomes, we used a dominant negative inhibitor of 
NF-κB. We then employed various approaches to find genes and proteins whose expressions are 
regulated by NF-κB and play a contributing role in the observed phenotypes. 
 
3.2   RESULTS 
3.2.1  Pro-inflammatory cytokine stimulations have different apoptotic effects on cell lines 
 Using a panel of four human liver cell lines which include two immortalized (HHL5 and 
HHL7) (Clayton et al., 2005) and two hepatocellular carcinoma (Hep3B and Focus), we 
examined the effect of pro-inflammatory cytokines including TNF-α and IL-1α on the apoptotic 
behaviors of these cell lines. To effectively assay for the apoptotic potential of these cytokines, 
we used superkiller TRAIL to induce cell death after they had been pre-treated with pro-
inflammatory cytokines. In this experimental setting, cells were plated and starved overnight 
before being treated with 100 ng/mL TNF-α or 10 ng/mL IL-1α for 2 hours (referred to as 2HR 
condition), 4 hours (referred to as 4HR condition) and overnight (referred to as O-N condition), 
after which 100 ng/ml TRAIL was added for another 24 hours with the pre-treated cytokines still 
in the media. Media was then removed and cells were washed, fixed and stained with methylene 
blue in 50% ethanol. The amount of cells remained was quantified by absorbance spectrometry. 
With this approach, we were able to observe different apoptotic outcomes that were time, 
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stimulus and cell line-dependent (Figure 3.1). Specifically, for HHL5 cells, both TNF-α and IL-
1α treatments conferred survival advantage against TRAIL killing. However, for HHL7 cells, 
only TNF-α and short-term IL-1α stimulations (2HR and 4HR) gave these cells pro-survival 
advantage while long-term IL-1α treatments (O-N) had no effects. For Focus cells, only pro-
survival behavior of TNF-α was observed while IL-1α appeared to have no effects regardless of 
the duration of treatment. For Hep3B cells, both long-term treatments with TNF-α and IL-1α 
made these cells more prone to be killed by TRAIL. A summary of the diverse apoptotic 
behaviors of cells pre-treated with pro-inflammatory cytokines followed by TRAIL is presented 
in Figure 3.2. When cells were treated with only TNF-α or IL-1α without TRAIL, we observed 
very little apoptotic effects induced by these two cytokines (Figure S-3.1) except for HHL7 cells 
where only a prolonged treatment with TNF-α for about 48 hours (O-N) resulted in ~25% cell 
death. Apparently, treating cells with pro-inflammatory cytokines alone did not give us much 
information about the apoptotic behaviors of these cells.  
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Figure 3.1  Apoptotic responses of human liver cell lines to pro-inflammatory cytokine pre-
treatment followed by TRAIL. (A, B, C, D) Responses of HHL5, Hep3B, HHL7 and Focus to 
TNF-α pre-treatments. Cells were starved overnight in serum free media. On day 1, cells were 
treated with 100 ng/mL TNF-α (referred to as O-N condition). On day 2, untreated cells were 
stimulated with 100 ng/ml TNF-α for 2 hours (referred to as 2HR condition) or 4 hours (referred 
to as 4HR condition) after which 100 ng/ml superkiller TRAIL was added to all TNF-α pre-
treated cells (O-N, 2HR, 4HR) and no media was changed. On day 3, dead cells were washed off 
and remaining cells were fixed and stained with methylene blue in 50% ethanol. Surviving cells 
were quantified by absorbance spectrometry and normalized to untreated cells. (E, F, G, H) 
Responses to HHL5, Hep3B, HHL7 and Focus to IL-1α pre-treatments. Experimental procedures 
were as in (A, B, C, D), except cells were pre-treated with 10 ng/ml IL-1α. Error bars represent 
the standard deviation of the mean of biological duplicates.  
 
 
 
 
Figure 3.2  Summary of apoptotic responses of human liver cell lines to pro-inflammatory 
cytokine pre-treatment followed by TRAIL. Short represents the 2 and 4 hours cytokine 
stimulations while long represents the overnight stimulations. 
 
 
3.2.2  NF-κB pathway is responsible for these diverse apoptotic outcomes   
 Since NF-κB pathway is known to be activated by pro-inflammatory cytokines, to 
examine whether this pathway is responsible for the diverse apoptotic outcomes described above, 
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we used a dominant negative inhibitor of NF-κB (referred to as IκB-DN). This inhibitor has two 
serine to alanine mutations (S32 and S36) (Boehm et al., 2007), which prevent it from being 
phosphorylated by an upstream kinase IKK and thus blocking the nuclear translocation of NF-κB 
and its activation. The inhibitor was introduced into cells by retroviral infection and cells with 
the inhibitor stably expressed were selected with puromycin. 
 Using cell lines carrying the stably expressed IκB-DN protein and employing the same 
experimental setting where cells were pre-treated with TNF-α or IL-1α for different durations 
and then with TRAIL, we asked whether blocking the activation of NF-κB pathway altered their 
apoptotic responses. For TNF-α stimulations, while treatment of this cytokine in the original 
HHL5 cells did not cause them to die (Figure S-3.1), the same treatment in the HHL5+IκB-DN 
killed as many cells as with the combined TNF-α and TRAIL treatments, suggesting that 
activation of the NF-κB pathway protects HHL5 cells from both TNF-α and TRAIL killing 
(Figure 3.3A, B). For IL-1α stimulations, both HHL5 and HHL5+IκB-DN cells showed no 
significant apoptotic effects. However, when treated with IL-1α and then TRAIL, only the 
original HHL5 cells exhibited resistance to TRAIL killing but not the HHL5+IκB-DN ones, 
further confirming that both TNF-α and IL-1α pre-treatments of HHL5 cells activated the NF-κB 
pathway which confers the observed pro-survival behaviors (Figure 3.3C, D). For TNF-α and IL-
1α stimulations, neither of these pro-inflammatory cytokines caused Hep3B or Hep3B+IκB-DN 
cells to die (Figure 3.4A, C). However, when treated with TNF-α or IL-1α overnight followed by 
TRAIL, only Hep3B cells exhibited the pro-death behavior, which can be blocked in 
Hep3B+IκB-DN cells, suggesting that the NF-κB pathway plays a pro-death role in this cell line 
(Figure 3.4B, D). For the remaining two cell lines HHL7 and Focus, overexpressing an IκB-DN 
protein was enough to eliminate any effects of pro-inflammatory cytokines pre-treatments 
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(Figure S-3.2, S-3.3). Taken together, it is evident that activation of the NF-κB pathway is 
responsible for the diverse apoptotic behaviors observed in these four liver cell lines. 
 
Figure 3.3  Apoptotic responses of HHL5+IκB-DN cells. (A, C) Responses of HHL5+IκB-DN 
cells to TNF-α and IL-1α alone. HHL5+IκB-DN cells were generated as described in the 
Materials and Methods section. Cells were starved overnight in serum free media. On day 1, cells 
were treated with 100 ng/mL TNF-α or 10 ng/ml IL-1α (referred to as O-N condition). On day 2, 
untreated cells were stimulated with 100 ng/ml TNF-α or 10 ng/ml IL-1α for 2 hours (referred to 
as 2HR condition) or 4 hours (referred to as 4HR condition). On day 3, dead cells were washed 
off and remaining cells were fixed and stained with methylene blue in 50% ethanol. Surviving 
cells were quantified by absorbance spectrometry and normalized to untreated cells. (B, D) 
Responses of HHL5+IκB-DN cells to TNF-α and IL-1α pre-treatments followed by TRAIL. 
Experimental procedures were as in (A, C), except on day 2, 100 ng/ml TRAIL was added. Error 
bars represent the standard deviation of the mean of biological duplicates.  
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Figure 3.4  Apoptotic responses of Hep3B+IκB-DN cells. (A, C) Responses of Hep3B+IκB-
DN cells to TNF-α and IL-1α alone. Hep3B+IκB-DN cells were generated as described in the 
Materials and Methods section. Experimental procedures were similar to those in (Figure 3.3A, 
C). (B, D) Responses of Hep3B+IκB-DN cells to TNF-α and IL-1α pre-treatments followed by 
TRAIL. Experimental procedures were as in (Figure 3.3B, D). Error bars represent the standard 
deviation of the mean of biological duplicates.  
 
 
3.2.3  Changes in the level of various pro- and anti-apoptotic proteins in response to pro-
inflammatory cytokines can help explain the phenotypic outcomes 
 As activation of the NF-κB pathway is responsible for diverse apoptotic responses, we 
sought to examine genes and proteins that have been implicated in the apoptotic pathway and 
whose expressions are under the control of the NF-κB transcription factor. To accomplish this, 
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we first collected NF-κB’s promoter binding data by carrying out a chromatin 
immunoprecipitation followed by high throughput sequencing (ChIP-Seq) experiment. To 
perform a ChIP-Seq assay, cells were starved overnight and then treated with 100 ng/mL TNF-α 
for 6 hours before being fixed with 1% formaldehyde for 10 minutes. Chromatin was extracted 
and sonicated to obtain DNA fragments in the 200-500 bp range. NF-κB’s bound promoters were 
immunoprecipitated with an antibody against its p65 subunit. The promoters’ regions were 
sequenced by an Illumina high throughput sequencing machine, which can sequence up to 30 
million reads per sample. We obtained the ChIP-Seq data from two hepatocellular carcinoma 
HepG2 and Focus as these data were already available to us. Because our primary goal for this 
step was to obtain as many promoters of genes that have a role in apoptosis, using data on 
HepG2 and Focus cells should suffice. Our sequencing results for HepG2 and Focus contained 
more than 13 million unique reads for each sample. From the promoters’ sequence data, we used 
the QuEST program (Valouev et al., 2008) to identify the chromosomal regions bound by NF- 
κB’s p65 in response to cytokine’s stimulation. We then used a second program GREAT 
(McLean et al., 2010) to find genes whose regions around transcription start sites (2000 bp 
upstream and 1000 bp downstream) include the promoter’s binding regions identified by QuEST 
(supplemental Table-S-3.1).  For our purpose, we only focused on genes that function in 
apoptosis (Table 3.1A).  
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Table 3.1  Candidate pro- and anti-apoptotic genes. (A) Genes obtained from ChIP-Seq 
analsyis. ChIP-Seq experiment was carried out as described in the Materials and Methods 
section. Sequencing data from ChIP-Seq were used as input for the QuEST program (Valouev et 
al., 2008), which generated peaks (transcription factor’s binding regions). The peaks data were 
then used as input for the GREAT program (McLean et al., 2010), which associated binding 
regions with genes and categorized them into functional groups. For our purpose, we focused on 
genes whose regions around transcription start sites (2000 bp upstream and 1000 bp 
downstream) contain the promoter’s binding sites identified by QuEST and also function in the 
apoptosis pathway. (B) Genes with known apoptotic functions. From the list of genes in (A), we 
then used the NF-κB database (see http://www.bu.edu/nf-kb/) which contains known NF-κB 
induced target genes with established functional studies to select only genes that are also present 
in the database.  
 
 To reduce the number of genes in Table 3.1A, we then chose only genes that were also 
present in the NF-κB database (see http://www.bu.edu/nf-kb/) which contains known NF-κB 
target genes with established functional studies (Table 3.1B). From this narrowed down group of 
genes, we examined whether their expressions changed in response to pro-inflammatory cytokine 
stimulations. For this experiment, cells were starved overnight and then treated with 100 ng/ml 
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TNF-α for 2.5 hours (representing the early response) and overnight (representing the late 
response), after which RNA samples were collected. Real-time PCR was performed and changes 
in genes’ expression were calculated as the fold-change in the qPCR signals between treated and 
untreated samples. Genes whose expressions showed at least two-fold changes in any stimulation 
conditions were presented (Figure 3.5). For HHL5 cells, in response to TNF-α treatments, 
upregulation of DR4, FLIP and RELA/p65 mRNA was observed. For Hep3B cells, TNF-α 
stimulations were seen to increase expression of BID, BAD, DR5 and FLIP. We also observed 
increases in expression of BIRC2 and BIRC3 genes in HHL5 and Hep3B cells (data not shown). 
However, since these genes appeared to function mainly as the pro-survival factors in the TNF-α 
induced cell death as their highest expression in Hep3B cells treated with TNF-α overnight could 
not prevent these cells from being killed by TRAIL, we decided not to include them in our study. 
 To further confirm the gene expression data, we measured the protein levels of these 
genes by Western blotting. To collect protein samples, cells were starved overnight and then 
treated with either 100 ng/mL TNF-α or 10 ng/mL IL-1α for 6 hours (representing the early 
response) and overnight (representing the late response). A BCA assay was carried out to 
quantify protein concentration and equal amounts of total protein were loaded for each sample. 
For HHL5 cells, we observed a very quick increase in the level of FLIP protein at the early time 
point and FLIP level stayed elevated at the late time point in response to both TNF-α and IL-1α 
stimulations (Figure 3.6A). A similar pattern for the NF-κB’s p65 protein was observed. On the 
other hand, the level of the death receptor DR4 showed a significant reduction with the overnight 
treatment of TNF-α and IL-1α. The Western blot data confirmed the qPCR data, except for DR4, 
which will be discussed later. Also, changes in proteins’ levels of FLIP, p65 and DR4 were not 
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observed in the HHL5+IκB-DN cells, indicating that the NF-κB pathway is responsible for these 
changes.    
 
 
Figure 3.5  Plots of mRNA expression of pro- and anti-apoptotic genes in TNF-α treated 
cells. (A, B) Relative mRNA level in HHL5 and Hep3B cells. HHL5 cells were starved 
overnight. On day 1, cells were treated with 100 ng/ml TNF-α. On day 2, untreated cells were 
stimulated with 100 ng/ml TNF-α for 2.5 hours, after which mRNA samples were extracted for 
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realtime PCR. Fold change was calculated based on the difference in the number of cycles 
between the TNF-α -treated and untreated cells. Error bars represent the standard deviation of the 
mean of biological duplicates.  
 
 
 For Hep3B cells, we observed an increase in the level of several pro-death proteins 
including BID and BAD in response to TNF-α and IL-1α treatments while in the Hep3B+IκB -
DN cells, such increase was effectively blocked (Figure 3.6B). This suggests that the NF-κB 
pathway plays a role in upregulating pro-apoptotic proteins in Hep3B cells which contributes to 
the observed pro-death behavior. For HHL7 cells, we observed similar changes in the level of 
FLIP, p65, DR4 and DR5 proteins when cells were treated with TNF-α as in HHL5 cells. 
However, when stimulated with IL-1α, only upregulation of FLIP and p65 was evident for the 
early response but no significant downregulation of DR4 and DR5 was observed at the late time 
point, which correlates well with the phenotypic outcomes described for this cell line when 
treated with IL-1α as this cytokine only induced a short-term pro-survival effects. For Focus 
cells, when treated with TNF-α, we observed similar changes in FLIP, p65, DR4 and DR5 
protein but to a smaller extent. However, IL-1α did not appear to produce any responses in this 
cell line at the phenotypic level or signaling or ChIP-Seq (data not shown), which suggests that 
Focus cells have no or non-functional IL-1α receptor.  
 To examine how the protein levels compare across all four cell lines, we loaded the same 
amounts of total protein for each sample and run them on the same Western blots (Figure 3.7). 
For DR4 protein, Focus, HHL5 and HHL7 expressed it at similar levels but Hep3B cells 
appeareed to lack this receptor. When cells were treated with TNF-α, HHL5 and HHL7, 
however, showed significantly more downregulation of this receptor compared to Focus. For 
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BID and BAD protein, Hep3B cells showed much higher expression of these pro-death proteins 
compared to the other three. For FLIP, this protein was upregulated strongly in HHL5 and HHL7 
in response to TNF-α and IL-1α. 
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Figure 3.6  Western blots of pro- and anti-apoptotic proteins in TNF-α and IL-1α treated 
cells. (A) Western blots of FLIP, DR4 and p65 in HHL5 and HHL5+IκB-DN cells. Cells were 
starved overnight. On day 1, cells were treated with 100 ng/ml TNF-α or 10 ng/ml IL-1α 
(referred to as O-N condition). On day 2, untreated cells were stimulated with 100 ng/ml TNF-α 
or 10 ng/ml IL-1α for 6 hours, after which whole cell lysates were collected for Western blots. A 
BCA assay was performed to determine protein concentration and equal amounts of total protein 
were loaded for each sample. (B) Western blots of BID and BAD in Hep3B and Hep3B+IκB-DN 
cells. Experimental procedures were as in (A). 
 
 
 
Figure 3.7  Western blots of pro- and anti-apoptotic proteins across four cell lines. Cells 
were starved overnight. On day 1, cells were treated with 100 ng/ml TNF-α or 10 ng/ml IL-1α 
(referred to as O-N condition). On day 2, whole cell lysates were collected for Western blots. A 
BCA assay was performed to determine protein concentration and equal amounts of total protein 
were loaded for each sample. Protein levels of DR4, DR5, BID, BAD, FLIP and p65 were 
measured. For Focus, since these cells did not response to IL-1α, only TNF-α treated samples 
were collected for this cell line. 
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3.3   DISCUSSION  
 In this study, we examined the pro-death and pro-survival potential of several human 
liver cell lines in response to pro-inflammatory cytokine treatments. We observed that pro-
inflammatory cytokines had different effects on the apoptotic outcomes of these cell lines when 
cells were pre-treated with either TNF-α or IL-1α followed by TRAIL. While HHL5 cells 
showed pro-survival effects with both TNF-α and IL-1α stimulations, HHL7 exhibited only pro-
survival behavior with TNF-α and short-term IL-1α treatments and Focus appeared to have only 
pro-survival response to TNF-α but not IL-1α. On the opposite end, Hep3B only displayed a pro-
death phenotype with both TNF-α and IL-1α. We then demonstrated that the NF-κB pathway 
was responsible for the diverse apoptotic outcomes induced by pro-inflammatory cytokines 
TNF-α and IL-1α as introduction of a dominant negative inhibitor of NF-κB (IκB -DN) into 
these cells effectively blocked such outcomes. 
 To investigate how activation of NF-κB gave rise to diverse phenotypic outcomes, we 
took several approaches. We first used ChIP-Seq data collected for two hepatocellular 
carcinomas HepG2 and Focus cells to obtain promoters’ regions bound by the NF-κB’s p65 
subunit in response to TNF-α. Next, we looked for candidate genes that lie close to these 
promoter regions and also have known functions in apoptosis. To further narrow the list of 
candidate genes, we only included genes which are also listed in the NF-κB database with 
existing functional studies. We then performed qPCR to measure changes in expression of these 
candidate genes in HHL5 and Hep3B cells treated with TNF-α. Genes that showed significant 
changes in their expression were selected for follow-up Western blotting. From the Western blot 
data, we observed that cells with pro-survival behaviors in response to TNF-α and IL-1α do so 
by upregulating p65 and FLIP and downregulating DR4 and DR5. The upregulation of p65 and 
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FLIP is more immediate, suggesting that this event is likely responsible for the early pro-survival 
phenotype whereas the downregulation of DR4 and DR5 occurs after a prolonged treatment of 
pro-inflammatory cytokines, implying that this event is more important in determining the late 
pro-survival behavior. For Hep3B cells that exhibit the pro-death response, upregulation of 
several apoptotic proteins including BID and BAD appears to play a contributing role. 
 Our results showed that TNF-α and IL-1α pre-treatments resulted in diverse apoptotic 
responses in four human liver cell lines, which suggests that there are underlying differences in 
their cellular networks. Since the NF-κB pathway was responsible for the various effects caused 
by TNF-α and IL-1α, this implies that activation of this pathway and the ensuing transcriptional 
programs are context (stimulus, time and cell type) dependent. Thus, using this type of context 
dependent approach will help us study different gene expression programs produced by the same 
transcription factor and also allow us to discover possibly new regulatory mechanisms. For 
example, in HHL5 and HHL7 cells, when treated with TNF-α overnight, we observed a sharp 
decrease in the level of DR4 and DR5 receptor and degradation products of these receptors were 
also evident on Western blots (Figure 3.8). On the mRNA level, when HHL5 cells were treated 
with TNF-α, expression of DR4 actually increased (Figure 3.5A) but we only observed an 
increase in this receptor at the protein level when the NF-κB was blocked (Figure 3.6A). The 
most likely explanation for this is when HHL5 and HHL7 cells are treated with TNF-α, 
expression of DR4, which appears to be independent of NF-κB, goes up but at the same time 
there is also an active degradation process that is dependent on the activation of NF-κB. In fact, 
it has recently been shown that DR4 and DR5 are subject to degradation by a ubiquitin-mediate 
process involving an E3-ubiquitin ligase c-Cbl (Song et al., 2010). This E3 ligase, however, is 
not an NF-κB’s target gene, so in our case there may be a different E3 ligase involved. Ongoing 
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efforts are underway to identify additional DR4 and DR5’s E3 ligases in HHL5 and HHL7 cells 
treated with TNF-α and IL-1α. 
 
 
Figure 3.8  Degradation products of DR4 and DR5. Western blots were performed as 
described in Figure 3.7. However, bands smaller than DR4 and DR5 molecular weight were also 
included, indicated by arrows. These bands most likely represent the degradation products of 
DR4 and DR5 in HHL5 and HHL7 treated with TNF-α and IL-1α. 
 
 Also, by using a context dependent approach, we were able to observe the pro-death 
behavior of Hep3B cells treated with either TNF-α or IL-1α. Since the NF-κB pathway was again 
shown to be responsible for such behavior, it implies that activation of this pathway in Hep3B 
cells actually has a pro-death effect, which is a less understood phenomenon as  NF-κB is 
thought to be mostly pro-survival. The pro-death effect of NF-κB was described as through the 
expression of death ligands such as FasL (Ho et al., 2011). However, treatment of Hep3B cells 
with both FasL and TRAIL together did not result in more cell death than treatment with TRAIL 
alone (data not shown). We believe that upregulation of several death proteins such as BID and 
BAD by NF-κB is directly responsible for the pro-death outcome of this cell line. In addition, we 
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also noticed that Hep3B cells show no or little expression of the DR4 receptor. Normally when 
cells with both DR4 and DR5 receptor are treated with TRAIL, these receptors form a 
heterotrimer. However, if one type of receptor is missing as in Hep3B, only a homotrimer of 
DR5 can be formed. It has been suggested that formation of different types of receptor’s trimers 
upon TRAIL stimulation can have different apoptosis outcomes (Lemke et al., 2010). Therefore, 
it will be interesting to examine cells having only one type of death receptor and whether this can 
contribute to altering the death response of those cells as seen for Hep3B. 
 The NF-κB pathway is known to be involved in activation of many genes. In our study, 
we only showed several genes and proteins with the most likely contribution to the overall 
apoptotic behaviors of various cell types based on the correlative changes in their expressions 
and the resulting phenotypes. However, this does not rule out the involvement of other genes and 
proteins regulated by NF-κB.  We are conducting a large scale expression profiling of these four 
cell lines in response to TNF-α and IL-1α using a Luminex bead-based mRNA measurement 
approach. This method can profile up to 1000 target gene expression per condition and can also 
process a large number of samples. We hope that with these types of data, we can uncover 
additional genes and proteins that not only play a role in the apoptosis pathway examined here 
but also other important cellular processes. 
 In vitro overexpression of p65 resulted in upregulation of FLIP and downregulation of 
DR4 (Chen et al., 2003). In our case, we also observed upregulation of FLIP and downregulation 
of DR4 together with upregulation of p65 in HHL5 and HHL7 in response to TNF-α and IL-1α 
in vivo. The increase in FLIP and the decrease in DR4 level were much more pronounced 
compared to that in Focus cells, where p65 was not upregulated significantly. This suggests that 
the dramatic changes in FLIP and DR4 protein levels in HHL5 and HHL7 cells are likely due to 
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the upregulation of p65. However, it is worth noting that at the protein level, p65 was only 
upregulated by about ~25% while at the mRNA level, p65’s mRNA was increased anywhere 
from 2-4 fold. Apparently, activation of the NF-κB pathway in HHL5 and HHL7 also regulates 
the expression of p65, which has not been usually the case. It is therefore interesting to see what 
cause the differences in p65’s regulation in HHL5 and HHL7 cells. 
 Inflammation in general and pro-inflammatory cytokines in particular play an important 
role in the function of our immune system. In addition, it has been observed that most tumors’ 
microenvironments are present with immune cells. Inflammation surrounding tumors has been 
suggested to confer many necessary properties for the growth and development of those tumors 
such as proliferation, angiogenesis as well as metastasis. Other important role of inflammation 
and pro-inflammatory cytokines involves apoptosis. As demonstrated in our study, pro-
inflammatory cytokines can potentiate very different apoptotic outcomes depending on the type 
of cytokines, time and cellular context. This has at least one important implication regarding 
cancer therapy using TRAIL. Due to its ability to kill tumors selectively, TRAIL has been used 
in clinical trials as a promising anti-cancer drug. However, our study highlights the importance 
of studying the microenvironment when using TRAIL as some pro-inflammatory conditions can 
result in TRAIL resistance.     
 Here, we have demonstrated that using a context dependent approach, we were able to 
reveal the complexity in the apoptotic behaviors of cells in response to pro-inflammatory 
cytokines. Starting from observations in apoptotic behaviors of cells pre-treated with pro-
inflammatory cytokines followed by TRAIL induced cell death, we set out to investigate the 
changes in gene and protein expression using various approaches. This helps us gain a better 
insight into the diversity, flexibility and dynamics nature of cellular responses, which gives us 
115 
 
additional clues into various mechanisms cells employ, be it receptor degradation or death 
receptor-specific apoptotic responses. The more we understand about the cellular programs and 
networks and their working mechanisms, the better we are at predicting their behaviors and 
ultimately at coming up with strategies to intervene and treat diseases.   
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3.4   MATERIALS AND METHODS  
Cell lines and Reagents  
Human liver cell lines, HHL5, HHL7, Hep3B and Focus were cultured in Eagle’s 
minimum essential medium (ATCC) plus 10% FBS, L-glutamine (Gibco), 1% 
penicillin/streptomycin and 20 mM HEPES. HEK 293T cells were cultured in DMEM with the 
same supplements as above. HHL5 and HHL7 cells were obtained from the Patel laboratory 
(University of Oxford, UK). HepG2 and Hep3B cells were purchased from ATCC, FOCUS cells 
were obtained from J. Wands (Brown University). The following antibodies were used: anti-p65 
(sc-109, sc-372 from Santa-Cruz); anti-FLIP (clone NF6, a gift from I. Lavrik, Heidelberg, 
Germany); anti-DR4 and DR5 (ProSci); anti-BID (Atlas Antibody); anti-BAD (sc-8044, Santa-
Cruz); anti-GAPDH (from Abcam). Other reagents were purchased from the following vendors: 
TNF-α and IL-1α from PeproTech; SuperKiller TRAIL (Alexis Biochemicals), SYBR reaction 
mix from Applied Biosystems. 
Pro-inflammatory cytokines and TRAIL treatment 
 Cells were seeded in 24-well plates at density of ~25%. The following day, media was 
changed to serum-free media to starve cells overnight. The next day (day 1), 100 ng/mL TNF-α 
or 10 ng/mL IL-1α was added for the overnight (O-N) treatment. On day 2, 100 ng/mL TNF-α or 
10 ng/mL IL-1α was added for 2 hours (2HR) or 4 hours (4HR) treatment followed by 100 
ng/mL TRAIL. On day 3, media and dead cells were removed, remaining cells were washed 
once with PBS and fixed and stained with 5 mg/mL Methylene Blue (Sigma) in 50% ethanol for 
30 minutes at room temperature. Cells were then washed 3 times with H2O and air-dried.  
Cell viability assay 
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To quantify cells on plates, 10 mg/ml sarcosine (Sigma) in PBS was added to the air-
dried cells for 30 minutes at room temperature. A duplicate of 100 µL solution from each well 
was transferred to two wells in a 96-well plate. Absorbance was read at 620 nm and 405 nm 
wavelength on a Victor3V Plate reader (Perkin Elmer) (protocol adapted from (Oliver et al., 
1989)). Fraction of cell surviving (percent survival) was calculated as the ratio of (Abs@620-
Abs@405) for a treated sample divided by (Abs@620-Abs@405) for an untreated control.  
Generation of cells expressing IκB-DN protein 
 293T cells were transfected with a pBabe-Puro-IκBalpha-mut (super repressor) 
(Addgene, Plasmid 15291) (Boehm et al., 2007) and pCL-ampho using Lipofectamine 2000 
(Invitrogen). Media was changed 4 hours post transfection. Viruses were collected after 24 and 
48 hours. HHL5, HHL7, Hep3B and Focus cells were infected with viruses for 24 hours. Cells 
stably expressing the IκB-DN proteins were selected using 1-4 µg puromycin (Invitrogen). 
Chromatin Immunopreciptation – high throughput Sequencing (ChIP-Seq) 
HepG2 and Focus cells were treated with TNF-α for 60 minutes followed by fixation 
with 10% formaldehyde (1% final concentration) for 10 minutes. Cells were lysed first in 
swelling buffer for 15 minutes (25mM HEPES pH 7.8, 1.5 mM MgCl2, 10mM KCl, 0.1% NP-
40, 1mM DTT, protease inhibitors (leupeptin, pepstatin, chymostatin) then in sonication buffer 
(50mM HEPES pH 7.8, 140mM NaCl, 1mM EDTA, 0.1% SDS, 1% TritonX-100 supplemented 
with protease inhibitors (leupeptin, pepstatin, chymostatin). Samples were sonicated for 3 
minutes with 20-second pulse intervals and 1 minute off at each interval at 4oC using a Fisher-
Scientific 550 Sonic Dismembrator with output setting at 4. Sonicated DNA fragment sizes were 
between 200-500bp. Chromatin was immunoprecipitated using an anti-p65 (sc-372 Ab from 
Santa-Cruz) and Dynabead Protein A (Invitrogen) at 4oC overnight. DNA was purified using 
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phenol/chloroform precipitation method. To prepare DNA for sequencing, adaptor oligos from 
the ChIP-Seq Sample Preparation Kit (llumina) were ligated to the ChIPed DNA per the 
manufacturer’s protocol. Samples were then submitted for high through sequencing on a 
Illumina HiSeq 2000 at the BioMicro Center at the Massachusetts Institute of Technology. 
Quantitative real-time PCR  
 mRNA samples were extracted from cells using the NucleoSpin RNA II kit (Macherey-
Nagel). cDNA synthesis was done using RETROscript kit with oligo (dT) (Applied Biosystems). 
qPCR reactions were performed in duplicate by using SYBR Green PCR Master Mix (Applied 
Biosystems) in the Eppendorf  Realplex Mastercycler S machine.  Primers are listed in 
supplementary Table S-3.2. The relative transcription level was calculated by using the ΔΔCt 
method with GAPDH as a normalization control. 
Western Blotting 
 Total cell lysates were collected by first washing cells once with cold PBS followed by 
adding lysate buffer (50mM HEPES pH 7.5, 10% glycerol, 100 mM NaCl, 0.1% SDS, 1% NP-
40, supplemented with protease inhibitors leupeptin, pepstatin, chymostatin and phosphatase 
inhibitors sodium orthovanadate, sodium fluoride, and beta-glycerol phosphate). Cells were 
lysed for 30 minutes on ice followed by centrifugation at 15000g for 15 minutes at 40C. Protein 
concentration was measured by a microBCA kit (Pierce). Equal amounts of total protein were 
loaded and run on a 8% SDS-PAGE gel. Separated proteins were transferred onto a 
nitrocellulose membrane which was then blocked with Odyssey Blocking Buffer (Li-COR) and 
probed with primary antibodies overnight at 40C. Detection was performed using secondary 
antibodies conjugated with IRDye 680 or 800 (Rockland) using a Li-COR Odyssey Scanner. 
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3.6   SUPPLEMENTAL INFORMATION 
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Figure S-3.1  Apoptotic responses of human liver cell lines to pro-inflammatory cytokines. 
(A, B, C, D) Responses of HHL5, Hep3B, HHL7 and Focus to TNF-α treatments. Cells were 
starved overnight in serum free media. On day 1, cells were treated with 100 ng/mL TNF-α 
(referred to as O-N condition). On day 2, untreated cells were stimulated with 100 ng/ml TNF-α 
for 2 hours (referred to as 2HR condition) or 4 hours (referred to as 4HR condition). On day 3, 
dead cells were washed off and remaining cells were fixed and stained with methylene blue in 
50% ethanol. Surviving cells were quantified by absorbance spectrometry and normalized to 
untreated cells. (E, F, G, H) Responses to HHL5, Hep3B, HHL7 and Focus to IL-1α pre-
treatments. Experimental procedures were as in (A, B, C, D), except cells were pre-treated with 
10 ng/ml IL-1α. Error bars represent the standard deviation of the mean of biological duplicates. 
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Figure S-3.2  Apoptotic responses of HHL7+IκB-DN cells. (A, C) Responses of HHL7+IκB-
DN cells to TNF-α and IL-1α alone. HHL7+IκB-DN cells were generated as described in the 
Materials and Methods section. Cells were starved overnight in serum free media. On day 1, cells 
were treated with 100 ng/mL TNF-α or 10 ng/ml IL-1α (referred to as O-N condition). On day 2, 
untreated cells were stimulated with 100 ng/ml TNF-α or 10 ng/ml IL-1α for 2 hours (referred to 
as 2HR condition) or 4 hours (referred to as 4HR condition). On day 3, dead cells were washed 
off and remaining cells were fixed and stained with methylene blue in 50% ethanol. Surviving 
cells were quantified by absorbance spectrometry and normalized to untreated cells. (B, D) 
Responses of HHL7+IκB-DN cells to TNF-α and IL-1α pre-treatments followed by TRAIL. 
Experimental procedures were as in (A, C), except on day 2, 100 ng/ml TRAIL was added. Error 
bars represent the standard deviation of the mean of biological duplicates.  
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Figure S-3.3  Apoptotic responses of Focus+IκB-DN cells. (A, C) Responses of Focus+IκB-
DN cells to TNF-α and IL-1α alone. Focus+IκB-DN cells were generated as described in the 
Materials and Methods section. Experimental procedures were similar to those in (Figure S-
3.2A, C). (B, D) Responses of Focus+IκB-DN cells to TNF-α and IL-1α pre-treatments followed 
by TRAIL. Experimental procedures were as in (Figure S-3.2B, D). Error bars represent the 
standard deviation of the mean of biological duplicates.  
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Table S-3.1  Gene promoters bound by p65 in response to TNF-α stimulation. HepG2 and 
Focus cells were treated with TNF-α for 60 minutes followed by fixation with 10% 
formaldehyde (1% final concentration) for 10 minutes. Chromatin was immunoprecipitated using 
an anti-p65 (sc-372 Ab from Santa-Cruz) and Dynabead Protein A (Invitrogen) at 4oC overnight. 
DNA was purified using phenol/chloroform precipitation method. To prepare DNA for 
sequencing, adaptor oligos from the ChIP-Seq Sample Preparation Kit (llumina) were ligated to 
the ChIPed DNA per the manufacturer’s protocol. From the promoters’ sequence data, the 
QuEST program (Valouev et al., 2008) was used to identify the chromosomal regions bound by 
NF- κB’s p65 in response to cytokine’s stimulation. A second program GREAT (McLean et al., 
2010) was employed to find genes whose regions around transcription start sites (2000 bp 
upstream and 1000 bp downstream) include the promoter’s binding regions identified by QuEST. 
 
Gene name Gene name Gene name Gene name 
A2LD1 FBXO46 MREG SESTD1 
AADACL4 FBXW4 MRPL14 SF3B14 
ABCA1 FCF1 MRPL19 SF3B2 
ABCC11 FCHSD2 MRPL27 SFRS12IP1 
ABCC4 FDPS MRPL34 SFRS15 
ABI1 FDXR MRPL39 SFRS18 
ABTB2 FERMT2 MRPS10 SFT2D2 
ACAP2 FGF11 MRPS18B SFT2D3 
ACAT2 FGF2 MRPS24 SH2B3 
ACP2 FGF6 MRPS33 SH3PXD2A 
ACSS1 FGF7 MRPS9 SHH 
ACSS3 FJX1 MSGN1 SIAH1 
ACTR8 FKBP10 MSH5 SIRPB1 
ADA FKBP1B MSH6 SIRT2 
ADAM17 FLII MT1B SIRT4 
ADAMTS9 FLJ16165 MT1F SIX4 
ADCK4 FLJ21075 MTF2 SKIL 
ADCK5 FLJ21511 MTHFR SKP2 
ADFP FLJ41766 MTMR14 SLC11A2 
ADM2 FLOT2 MUC2 SLC15A1 
ADPRH FMNL1 MUC5AC SLC16A6 
AFMID FMNL3 MUT SLC20A1 
AFTPH FN1 MVD SLC20A2 
AGBL5 FNTA MXD3 SLC25A37 
AGMAT FOXJ1 MYBPC1 SLC25A39 
AGPAT4 FOXK1 MYCL1 SLC26A1 
AGRN FOXO3 MYH9 SLC27A5 
AGT FRAS1 MYL5 SLC2A6 
AGXT FSCN1 MYNN SLC30A7 
AHNAK FSTL3 MYO1B SLC33A1 
AHSA2 FTH1 MYO1D SLC34A2 
AIM2 FUK MYO5C SLC35D2 
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AK3 FUT5 MYOM1 SLC37A4 
AKAP1 FUT6 MYPOP SLC39A14 
AKR1A1 FXR1 NAGLU SLC39A7 
AKR1B1 FXYD2 NAGPA SLC3A2 
AKR1D1 FZD6 NAP1L1 SLC41A2 
ALDH7A1 FZD7 NAV2 SLC43A3 
ALG10 FZD9 NBN SLC44A1 
ALG11 G0S2 NBR1 SLC46A3 
ALG6 G3BP1 NCF4 SLC48A1 
ALMS1 GABARAPL2 NCOA4 SLC5A1 
ALOX5 GADD45A NDRG4 SLC5A10 
ALOX5AP GADD45G NDST1 SLC6A14 
AMBRA1 GAK NDUFA2 SLC8A1 
AMIGO2 GAMT NDUFAF1 SLC9A8 
AMOTL2 GAPDH NDUFB7 SLC9A9 
AMPD3 GATA4 NDUFS7 SLMAP 
ANKRD1 GBA NDUFV1 SMAD3 
ANKRD2 GBAS NDUFV2 SMARCA1 
ANO9 GCDH NECAP2 SMARCA4 
ANP32E GCH1 NEDD9 SMARCC2 
ANXA2 GCLC NEK6 SMCHD1 
ANXA4 GCS1 NEK8 SMG7 
ANXA5 GDAP1 NEURL2 SMPD2 
ANXA8L2 GDE1 NEURL4 SNAP23 
AOF1 GDF15 NFAT5 SNAPC4 
AP2B1 GDPD5 NFE2 SNRPE 
AP4E1 GFAP NFE2L3 SNX15 
APOA1 GGA1 NFIB SOD1 
APOA2 GGCX NFKB1 SOD2 
APOA5 GGT1 NFKBIB SORL1 
APOB GHRHR NIACR2 SP3 
APOC3 GHRL NIN SP5 
APOF GIMAP8 NINJ1 SPATA5 
AQR GJC1 NIPSNAP1 SPINT3 
ARFGAP3 GK NLRC4 SPPL2A 
ARFGEF2 GLCE NMNAT1 SPR 
ARG1 GLT8D4 NOD2 SPSB1 
ARL14 GLTPD2 NOL11 SPSB4 
ARL2BP GMDS NOLC1 SPTBN1 
ARL4C GMNN NOP16 SQSTM1 
ARL5B GNA15 NOTUM SREBF2 
ARL6IP5 GNAI2 NPB SRP14 
ARNTL2 GNB1 NQO1 SRPK1 
ARPC5 GNG12 NQO2 SSB 
ARRB1 GNPAT NR1I3 SSBP3 
ART4 GOLT1A NRARP SSH1 
ASB6 GOLT1B NRAS SSSCA1 
ASCL2 GORASP2 NRBF2 SSTR2 
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ASNSD1 GP1BA NSFL1C ST3GAL3 
ASS1 GPC6 NSL1 ST5 
ATAD2B GPR126 NSMCE1 ST7 
ATG4B GPR137 NT5DC3 STAG1 
ATG7 GPR142 NTAN1 STAP2 
ATOH8 GPR176 NUAK1 STARD3 
ATOX1 GPR37L1 NUAK2 STARD3NL 
ATP5G1 GPR44 NUDT6 STARD4 
ATP5I GPR88 NUP153 STAT5A 
ATP6V1E2 GPR97 NUP35 STC2 
ATP7B GPRC5A NUP54 STEAP2 
AURKB GPX1 NUP93 STOML1 
AZIN1 GREB1 NUSAP1 STX4 
B2M GRHL1 NXT2 STXBP5 
B4GALT1 GRIPAP1 OAS3 SULT1A2 
B4GALT5 GRN OGFOD2 SULT1C4 
BAD GSTO1 OIP5 SUPT4H1 
BAIAP2L1 GTPBP2 OLR1 SUPV3L1 
BAT2D1 GUCY1B2 OPA3 SVIL 
BATF GULP1 OR4K5 SYDE1 
BAX GYPC OR5B3 SYNGR2 
BAZ1A H1FX OR5H1 SYS1 
BBC3 H2AFY2 OR7G3 SYT12 
BCAT1 H3F3B ORAI1 SYT8 
BCL2L1 H6PD ORM1 TACSTD2 
BCL3 HARBI1 ORMDL3 TAGLN2 
BCL6 HAVCR1 OSGIN1 TANK 
BCL7A HBS1L OTC TAP1 
BET3L HCN4 OVOS2 TAPBP 
BHLHE40 HDGFRP3 P2RY5 TATDN3 
BID HDHD3 PACS1 TBC1D22B 
BIRC2 HEATR2 PAF1 TBCA 
BIRC3 HECTD1 PAK1 TBL1X 
BMP2K HEG1 PALM2-AKAP2 TBL1XR1 
BNIP1 HES1 PAN2 TBP 
BNIP3 HIF1AN PANK1 TBX4 
BOLA1 HIGD2A PANX1 TBX6 
BPHL HINT1 PAPSS2 TCEA2 
BRAF HIST1H4I PAQR8 TCEB1 
BRE HIST1H4J PARP1 TCF7L2 
BRMS1L HIST1H4K PARP12 TERF2IP 
BRWD2 HIST4H4 PBX2 TESK2 
BSDC1 HIVEP1 PBX4 TESSP2 
BTG3 HIVEP2 PCBP3 TEX101 
BTG4 HLA-A PCK1 TFE3 
BTN2A1 HLA-DQB1 PCTK2 TGFBR3 
BTN2A2 HMGXB4 PDCD1LG2 TGIF2 
BTN2A3 HNF1A PDCD2L TGM2 
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BTNL9 HNF1B PDCD5 THAP4 
C1D HNMT PDCD7 THEM2 
C1RL HNRNPC PDE4A TIFA 
C1S HNRNPL PDE4DIP TIGD2 
C3 HOMEZ PDE6D TINAG 
C4BPB HOOK3 PDE6G TINAGL1 
C9 HOXD1 PDE8A TINF2 
CACHD1 HOXD10 PDGFC TIPARP 
CACNG1 HOXD11 PDLIM4 TJP2 
CALML5 HOXD12 PERLD1 TK1 
CAMK2D HOXD13 PEX13 TLCD1 
CAP2 HPD PEX26 TLE1 
CAPG HPN PFDN4 TLE4 
CARHSP1 HPS4 PFN1 TLN1 
CASP10 HS3ST6 PFN2 TLR2 
CASP4 HSD11B1 PGBD5 TLR6 
CCBL2 HSPA1A PGC TM9SF2 
CCDC115 HSPA1L PGLYRP2 TMCC2 
CCDC76 HSPA4L PGM3 TMEFF1 
CCL16 HSPC159 PGPEP1 TMEM106A 
CCL20 HSPG2 PHACTR2 TMEM115 
CCL21 HTATSF1 PHF1 TMEM132A 
CCL4 HTR2B PHF10 TMEM140 
CCNB1IP1 HTRA4 PHKG2 TMEM141 
CCNC HYAL3 PHLDA3 TMEM165 
CCNG1 ICAM1 PHYH TMEM189 
CCNG2 ICAM2 PI3 TMEM19 
CCRN4L ICAM4 PIGV TMEM205 
CD209 ICK PIK3CD TMEM217 
CD38 IDH1 PIM1 TMEM43 
CD44 IFIH1 PIM3 TMEM63B 
CD48 IFIT3 PKM2 TMEM69 
CD70 IFLTD1 PLA2G2D TMEM77 
CD74 IFNAR1 PLA2G2E TMEM98 
CD82 IFNAR2 PLA2G4C TMPRSS9 
CDK6 IFT20 PLA2G6 TMTC2 
CDKN2C IGF2 PLAU TNFa 
CDYL IGF2BP1 PLCB3 TNFAIP1 
CEBPB IGF2R PLEC1 TNFAIP2 
CEBPG IGFALS PLEKHH3 TNFAIP3 
CENPQ IGFBP1 PLK3 TNFRSF10B 
CEP135 IGFBP7 PLXNB1 TNFRSF1B 
CETP IK PLXNB2 TNFRSF4 
CFB IKBKE PMAIP1 TNFRSF6B 
CFL2 IKZF3 PNPLA6 TNFRSF9 
CFLAR IL13 PNRC2 TNFSF14 
CGN IL17RB POLRMT TNIP1 
CGNL1 IL1A POMGNT1 TOB2 
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CGRRF1 IL1F8 POP4 TOMM5 
CHCHD4 IL1RN PPAPDC1B TP53 
CHD6 IL20 PPFIBP2 TP53I3 
CHDH IL23A PPIL6 TPCN1 
CHMP1B IL3RA PPP1R10 TPI1 
CHMP4B IL4I1 PPP1R14D TPK1 
CHRNA10 IL7 PPP1R15A TPMT 
CHST13 IL7R PPP1R15B TPT1 
CHST4 IL8 PPP1R9B TRAF1 
CIB4 IMP4 PPP3CC TRAF2 
CITED2 INF2 PPP4R1L TRAF3 
CKAP4 INHBC PPYR1 TRAF4 
CKS2 INHBE PRDX2 TRAPPC10 
CLCN6 INO80B PRELID1 TRAPPC3 
CLDN16 IP6K3 PRM1 TRIB1 
CLEC4E IQGAP2 PRMT1 TRIB3 
CLGN IRAK2 PRND TRIM16L 
CLIC4 IRAK3 PRPF3 TRIM21 
CLIP2 IRF1 PRPF40B TRIM25 
CLK4 IRF2BP2 PRPF6 TRIM27 
CLTB IRF5 PRRG4 TRIM31 
CMTM6 IRF6 PSMA6 TRIM41 
COASY IRX4 PSMB1 TRIM44 
COL7A1 ISG20 PSMB9 TRIM47 
COQ10B ISG20L2 PSME1 TRIM67 
COQ6 ISM1 PSME2 TRIM8 
CORO1C ITFG1 PTBP1 TRNP1 
CORO2B ITGAD PTER TRPM7 
COX4I1 ITGAE PTGES TRPV2 
COX4NB ITGAM PTGR2 TRPV3 
CP ITGB2 PTHLH TSEN2 
CP110 ITGB6 PTK6 TSGA10 
CPAMD8 ITGB8 PTP4A2 TSKU 
CPLX2 ITIH1 PTPN1 TSNAXIP1 
CPSF3 ITIH2 PTTG1IP TSPAN11 
CPT2 ITPKC PTX3 TSPAN14 
CRADD ITSN2 PUS10 TSPAN15 
CRAMP1L IVD PVR TSPAN31 
CREB3 IWS1 PXK TTC12 
CREB5 JAK3 QKI TTC21B 
CRTC2 JAM2 QTRT1 TTC22 
CRY2 JARID2 QTRTD1 TTC23 
CRYZ JDP2 RAB11B TTC27 
CSAD JUB RAB34 TTC32 
CSF1 JUNB RAB37 TTC7A 
CSF3 KARS RAB42 TTPA 
CSNK1G2 KBTBD7 RAC1 TTRAP 
CST5 KCNJ13 RAD51L1 TUBA1C 
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CSTB KCNN3 RAD52 TUSC4 
CSTF2 KCNQ4 RANBP10 TUT1 
CTDSP1 KCTD11 RANBP2 TWISTNB 
CTGF KIF20B RANGAP1 TYK2 
CTHRC1 KIF2C RAP1A TYMP 
CTPS KIF3C RAP2C TYW3 
CTSA KIFC1 RAPGEF2 UBD 
CTSC KLC1 RAPH1 UBE2H 
CTSS KLF10 RARS UBE2O 
CXCL1 KLF9 RASA2 UBE2W 
CXCL10 KLHL38 RASL12 UBE2Z 
CXCL2 KREMEN2 RASSF10 UBQLN4 
CXCL3 KRT32 RASSF2 UEVLD 
CXCR6 KRT6B RAX UGT2A3 
CYB5R2 KRT75 RB1 UNC119 
CYB5R3 KRTAP2-4 RBKS UNC84B 
CYBA KRTAP3-1 RBM15B UPK3A 
CYCS KRTAP3-2 RBM19 UQCRB 
CYP27A1 KTELC1 RBM28 UQCRC2 
CYP27B1 KYNU RBM39 UQCRHL 
CYP4F11 L3MBTL4 RBM9 USP12 
CYP4F8 LACTB RBMS3 USP13 
CYP8B1 LAD1 RBX1 USP16 
DARS LAMB3 RCOR3 USP3 
DCBLD2 LAMC2 RDH16 USP37 
DDX39 LAPTM4A RELA USP49 
DDX58 LARP4 REM1 USP54 
DENND5A LARP6 REPIN1 USP7 
DET1 LASS4 REPS1 USPL1 
DHCR24 LBP RERE UVRAG 
DHFR LBX2 RETSAT UXS1 
DHRS7B LCN2 RFX2 VASN 
DHX33 LCP2 RFX5 VDAC1 
DIAPH2 LCTL RFXANK VDR 
DICER1 LDHAL6B RGL1 VEZF1 
DLD LDLRAD1 RHBDL2 VMO1 
DNAH1 LEFTY1 RHOF VNN3 
DNAJB2 LFNG RHOV VPS16 
DNAJC10 LGALS1 RIN1 VPS18 
DNAJC2 LGALS8 RIPK2 VPS28 
DNAJC5 LGR5 RNASE8 VPS37C 
DOCK10 LIMD2 RNASEK VSNL1 
DOT1L LIMK2 RND1 VTA1 
DPP4 LIMS1 RNF114 VTN 
DPP9 LINCR RNF126 WAC 
DR1 LIPT1 RNF135 WDR36 
DRAP1 LMAN1 RNF144A WDR75 
DTX4 LMBRD2 RNF149 WDTC1 
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DUSP11 LPGAT1 RNF151 WHSC2 
DUSP22 LPXN RNF170 WRAP53 
DUSP5 LRCH1 RNF181 WWC1 
DUSP6 LRCH3 RNF186 XAF1 
DYRK3 LRG1 RNF207 XKR7 
DZIP3 LRRC1 RNF24 YY1AP1 
E2F6 LRRC59 RNF31 ZBBX 
EBF4 LRRC61 RNMTL1 ZBTB1 
EBI3 LRRFIP2 ROBLD3 ZBTB17 
ECT2 LSS ROBO4 ZBTB25 
EDAR LTA ROR1 ZBTB26 
EDC4 LTB RPGRIP1 ZC3H10 
EDEM3 LTBP2 RPH3AL ZC3H12A 
EFHD2 LY75 RPL23 ZC3H12C 
EFNA1 LY86 RPL27A ZC3H12D 
EGR1 LY96 RPL5 ZC3H7A 
EHD1 LYRM1 RPRD2 ZC3H7B 
EIF1 LYRM4 RPS16 ZCCHC8 
EIF2B3 LZIC RPS2 ZDHHC18 
EIF3E MAD2L1BP RPS3 ZF6 
EIF4A2 MAFF RPS5 ZFAND3 
EIF4EBP2 MAGOHB RPS6KB2 ZFHX3 
EIF5A MAL2 RPUSD4 ZFP36L1 
EIF6 MAML2 RQCD1 ZFP42 
ELF4 MAN1A1 RRAD ZFP91 
ELF5 MAN2C1 RRAS ZKSCAN3 
ELL2 MAP2K2 RRBP1 ZMIZ2 
ELMO2 MAP3K2 RTTN ZNF101 
ELMOD3 MAP4 RXRB ZNF192 
EME1 MAP4K4 S100A10 ZNF2 
EMILIN1 MAPK14 SAA1 ZNF223 
ENC1 MAPK6 SAA2 ZNF24 
EPHA2 MARCKS SAA4 ZNF267 
EPRS MBIP SAE1 ZNF3 
EPS8 MCCC2 SALL4 ZNF317 
ERGIC1 MCHR1 SAPS3 ZNF318 
ESPL1 MCM2 SARM1 ZNF323 
ETFA MDM2 SASS6 ZNF335 
ETFB MED18 SAT1 ZNF33B 
ETFDH MED29 SBK1 ZNF354B 
ETV6 MEF2B SBNO2 ZNF426 
EVX2 MEFV SC65 ZNF436 
EXTL2 MEIS1 SCAMP3 ZNF44 
EZH1 MET SCARA3 ZNF500 
F11 MFSD10 SCARA5 ZNF546 
F2 MFSD4 SDCCAG10 ZNF554 
F3 MGLL SDR9C7 ZNF605 
FABP1 MGRN1 SEC16A ZNF670 
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FAM110A MGST2 SEC22B ZNF687 
FAM111A MIA2 SEC24A ZNF688 
FAM113A MICAL2 SEH1L ZNF697 
FAM120B MKKS SELK ZNF699 
FAM129A MKNK2 SEMA4G ZNF7 
FAM150B MLL5 SENP3 ZNF706 
FAM151A MLLT6 SEPP1 ZNF718 
FAM36A MMADHC SEPSECS ZNF740 
FAM69A MMD SERINC4 ZNF747 
FAM82B MME SERPINA11 ZNF749 
FAM8A1 MMP2 SERPINA12 ZNF764 
FARS2 MMP9 SERPINA6 ZNF768 
FBLN2 MOBKL2C SERPINC1 ZNF781 
FBRS MOGAT2 SERPIND1 ZNF799 
FBXL19 MORC3 SERPINE1 ZNFX1 
FBXO15 MRAS SERPINF2 ZNRF1 
   ZSWIM4 
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qPCR primers 
Target gene Forward (5’- 3’) Reverse (5’- 3’) 
DR4 CCACCACCAGCTAGAGTACAT GGAAGAGCCCCACACTTT 
DR5 AAGACCCTTGTGCTCGTTGTC GGGCTGGACCTCTTTTGTTGT 
BID CCTACCCTAGAGACATGGAGAAG TTTCTGGCTAAG CTCCTCACG 
BAD CCCAGAGTTTGAGCCGAGTG CCCATCCCTTCGTCGTCCT 
FLIP GACAGAGCTTCTTCGAGACAC GCTCGGGCATACAGGCAAAT 
RELA (p65) CTGCCGGGATGGCTTCTAT CCGCTTCTTCACACACTGGAT 
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
 
Table S-3.2  Primers for realtime PCR (listed in the 5’ to 3’ direction). 
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Chapter 4:  Conclusions 
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4.1   Summary of main findings 
 The goal of this thesis was to understand the role of intra- and extra-cellular modulators 
of NF-κB. To this end, I have shown that intracellular proteins that interact and modify NF-κB 
affect its gene-specific regulation and extracellular stimuli that activate NF-κB in a context-
dependent manner greatly influence cellular responses. 
 In chapter 2, I used affinity purification and mass spectrometry to identify proteins that 
interact with human p65/RELA, one of the most abundant components of the NF-κB 
transcription factor.  Follow-on co-immunoprecipitation experiments confirmed the interaction 
(direct or indirect) of the serine/threonine kinase STK38 and its close homologue STK38L with 
p65.  shRNA-mediated knockdown of both STK38 and STK38L reduced NF-κB –mediated 
transactivation of TNF-α-responsive genes such as LTB and TNF as well as binding of p65 to 
LTB and TNF promoters. In vitro kinase assay showed that p65 is an STK38/38L substrate and 
that phosphorylation of p65 at S356 site is necessary for full LTB and TNF induction in vivo.  
 In chapter 3, I examined the pro-death and pro-survival potential of several human liver 
cell lines in response to pro-inflammatory cytokine treatments. I showed that pro-inflammatory 
cytokines had different effects on the apoptotic outcomes of these cell lines when cells were pre-
treated with either TNF-α or IL-1α followed by TRAIL. The observed behaviors were very 
context (cell type, stimulus and time)-dependent. I then demonstrated that the NF-κB pathway 
was responsible for the diverse apoptotic outcomes induced by pro-inflammatory cytokines 
TNF-α and IL-1α as introduction of a dominant negative inhibitor of NF-κB into these cells 
effectively blocked such outcomes. To investigate how activation of NF-κB gave rise to diverse 
phenotypic outcomes, I took several approaches. I first used ChIP-Seq data to obtain promoters’ 
regions bound by the NF-κB’s p65 subunit in response to TNF-α.  qPCR and Western blotting 
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were performed to measure changes in expression of candidate genes. Cells with pro-survival 
behaviors in response to TNF-α and IL-1α were found to do so by upregulating p65 and FLIP 
and downregulating DR4 and DR5. The upregulation of p65 and FLIP is more immediate, 
suggesting that this event is likely responsible for the early pro-survival phenotype whereas the 
downregulation of DR4 and DR5 occurs after a prolonged treatment of pro-inflammatory 
cytokines, implying that this event is more important in determining the late pro-survival 
behavior. For cells that exhibit the pro-death response, upregulation of several apoptotic proteins 
including BID and BAD appears to play a contributing role. 
 
4.2   Relevance of this work 
4.2.1  New mediators of NF-κB in inflammation 
NF-κB family proteins have been found to play important roles in many aspects of the 
immune system during differentiation of immune cells, development of lymphoid organs and 
during immune activation (Hoffmann and Baltimore, 2006). Research on the biological function 
of NF-κB has largely concentrated on the mechanisms of signaling that lead to NF-κB activation 
(Wan and Lenardo, 2010). However, it has been recognized that binding of NF-κB complexes to 
target DNA might not be sufficient for full gene transcription. Emerging evidence suggests that 
additional events are required. Like many pleiotropic transcription factors such as p53, NF-κB 
activity is now known to be regulated by posttranslational modifications as well as co-activators 
and co-repressors (Natoli and De Santa, 2006).  
Dysregulation of NF-κB has been implicated in many inflammatory diseases such as 
rheumatoid arthritis, asthma, inflammatory bowel diseases, liver fibrosis and cirrhosis (Baud and 
Karin, 2009; Sun and Karin, 2008). Most current drugs that inhibit NF-κB suffer significant side 
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effects due to non-selectivity. The ability to effectively target NF-κB for therapeutic intervention 
requires an understanding of the intricate relationships between NF-κB signaling pathways and 
the variability in the expression pattern of NF-κB-regulated genes. This involves the 
identification of new regulatory components of the NF-κB pathway that regulate selectivity in 
the activation of NF-κB transcriptional programs. 
Both TNFα and LTβ belong to the TNF superfamilies of ligands (Balkwill, 2006; 
Schneider et al., 2004). While TNFα activates NF-κB primarily via the canonical pathway, LTβ 
does so via the non-canonical pathway. The lymphotoxin system is involved in the development 
of secondary lymphoid organs, in the formation of ectopic lymphoid structures and in the 
organization of lymphoid microenvironments (Gommerman and Browning, 2003). TNF-α is, on 
the other hand, involved in the maintenance and homeostasis of the immune system, 
inflammation and host defense. Together, both cytokines and their corresponding signaling 
systems play an important role in the development and function of the immune system. 
In this work, two additional NF-κB’s coactivators, STK38 and STK38L were identified. 
These two kinases were shown to modulate the expression of TNFα and LTβ. Overproduction of 
TNF is the main cause of many inflammatory diseases. Most inhibitors of TNF synthesis work 
by blocking upstream components of NF-κB’s signaling pathway such as IKK. However, 
blocking NF-κB completely can have side effects as this transcription factor is involved in many 
important cellular functions. An alternative approach is to selectively inhibit TNF production 
without too much interference with NF-κB’s functions. Targeting STK38 and STK38L instead 
might help accomplish this.  
 
4.2.2  The importance of contexts in understanding cellular responses 
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 NF-κB is a pleiotropic transcription factor that involves in regulating the expression of 
many genes. NF-κB-dependent genes control the inflammatory and immune responses, 
programmed cell death, cell proliferation and differentiation. A variety of stimuli can activate 
NF-κB via several main groups of receptors such as the TNF receptors family, the pattern-
recognition Toll like receptors (TLR), the IL-1 receptors and the antigen receptors 
(Vallabhapurapu and Karin, 2009). These receptors can potentially activate not only different 
members of the NF-κB family but also other intracellular signaling and enzymatic proteins, 
which together results in the induction of a unique gene transcription program dependent on NF-
κB. 
 While NF-κB signaling pathways activated by various stimuli are very complex, a single 
NF-κB pathway induced by a single ligand is not simple either. As demonstrated in this work, 
the same TNFα or IL-1α stimulation can have very different effects on cellular responses 
including the programmed cell death. While in some cells, TNFα and IL-1α confer pro-survival 
advantage against TRAIL killing, in other cells, the effect is the opposite. In addition, duration of 
TNFα and IL-1α treatments can also have distinct outcomes. Since activation of NF-κB is 
necessary, this implies that different NF-κB gene regulation programs are responsible for such 
diverse behaviors. This shows that NF-κB responses are very context-dependent, be it cell type, 
stimulus or time. In order to understand how NF-κB functions, it is therefore important to look at 
the context surrounding its activation. Although this undoubtedly increases the complexity of the 
NF-κB signaling pathway, it also provides us with valuable information about different NF-κB’s 
gene expression programs, from which insights into how NF-κB’s target genes are regulated and 
discovery of new regulatory mechanisms can be gained. In this work, applying a context-
dependent approach, several TRAIL resistance mechanisms were proposed. The first mechanism 
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involves upregulation of FLIP and the second mechanism involves downregulation of TRAIL 
receptors DR4 and DR5. While FLIP upregulation is very fast, downregulation of DR4 and DR5 
happens at a much later time. Some cells can effectively activate both mechanisms with the first 
one as the early response to pro-inflammatory cytokines and the second one as the late response. 
Also, upregulation of NF-κB’s p65 subunit appears to play a key role in changes in FLIP and 
DR4 and DR5 protein levels. While p65 directly up-regulates FLIP, it indirectly down-regulates 
DR4 and DR5 by possible turning on a ubiquitin-mediated degradation of these receptors.   
  
4.2.3  Pro-death role of NF-κB  
 NF-κB is mostly known for its pro-survival function as p65 deficient cells undergo 
apoptotic cell death upon treatment with TNFα due to inadequate pro-survival gene transcription 
(Beg and Baltimore, 1996). In addition, p65 knockout cells lead to embryonic lethality 
accompanied by massive apoptosis in the embryonic liver due to TNFα exposure (Beg et al., 
1995). Also, in response to other stimuli such as ionizing radiation and chemotherapeutic drugs, 
p65 appears to have an anti-apoptotic effect (Barkett and Gilmore, 1999).  
While the pro-survival role of NF-κB has been extensively characterized, little is known 
about its pro-death function and the mechanism by which NF-κB mediates a pro-death response 
is not well characterized. Recent studies suggest that the pro-death function of NF-κB is due to 
its repression of pro-survival genes such as Bcl-2 and XIAP and induction of pro-death genes 
namely TNFα and Fas ligand (Ho et al., 2011). 
 In this work, in response to pro-inflammatory cytokine TNFα and IL-1α stimulation 
followed by TRAIL, Hep3B cells were shown to exhibit a pro-death phenotype. NF-κB was 
demonstrated to be responsible for this outcome as blocking its activation prevented the pro-
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death behavior. However, the pro-death function of NF-κB in this cell line was not due to 
repression of pro-survival genes as their expression could still be detected. It is mainly the 
upregulation of pro-death genes that contributes to the observed response. Interestingly, the type 
of pro-death genes induced by NF-κB in Hep3B cells is rather different from what was shown in 
other studies which suggested that the pro-death role of NF-κB was due to TNFα and FasL 
synthesis. In fact, neither TNFα nor FasL alone was able to kill Hep3B cells. Taken together, this 
work not only described the pro-death function of NF-κB but also suggested a different 
mechanism for such function. 
 
4.2.4  Inflammation and cancer 
 It has long been suspected that there is a link between inflammation and cancer based on 
observations that virtually every tumor is surrounded by immune cells (Hanahan and Weinberg, 
2011). Such immune responses were originally thought of as an attempt by the immune system 
to eradicate tumors, which is true in some cases. However, tumor-associated inflammation has 
been shown to have an unanticipated effect of enhancing tumorigenesis and progression. 
Inflammation can cause the release of cytokines to the tumor microenvironment that can 
facilitate proliferation, survival, angiogenesis, invasion, metastasis, and activation of epithelial-
mesenchymal transition. 
 Elevated NF-κB activity has been observed in many solid tumors. In such cancers, NF-
κB activation is a result of the underlying inflammation or the consequence of formation of an 
inflammatory microenvironment during malignant progression. Genes regulated by NF-κB can 
affect all aspects of cancer development including inhibition of apoptosis, stimulating cell 
proliferation as well as promoting a migratory and invasive phenotype. Thus, NF-κB is believed 
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to play a critical role in the intricate relationship between inflammation and cancer (Karin, 2009; 
Karin et al., 2002).  
 While the important role of inflammation in tumorigenesis has now been recognized, it is 
still not easy to study this relationship in vivo. An alternative approach is therefore to use an in 
vitro cell culture system to explore how inflammation affects various aspects of cell behaviors. 
In this work, such in vitro approach was used to study the role of pro-inflammatory cytokines in 
the apoptotic responses of human liver cells. Using this type of approach, diverse apoptotic 
behaviors were observed. This suggests that inflammation has different effects on different cells 
and that these diverse behaviors reflect the complex and distinct gene transcription programs 
regulated by NF-κB. Although, this in vitro context-dependent approach was applied to 
investigate only the cell death and survival aspects induced by inflammation, there is no reason 
why such approach cannot be used to explore other inflammation-induced pathways. 
 Given the role of inflammation in cancer and the fact that tumor cells respond to 
inflammation differently, one has to take all of these into consideration when it comes to cancer 
treatment. An example of this involves TRAIL. This promising anti-cancer drug has attracted 
considerable attention owing to its selective killing of tumor cells while normal cells were 
largely protected (LeBlanc and Ashkenazi, 2003). In animal models, treatment with TRAIL by 
itself or in combination with other drugs resulted in suppression of tumor xenografts without 
causing systemic toxicity (Kelley and Ashkenazi, 2004). Clinical trials using TRAIL have been 
reported for patients with non-small-cell lung cancer, non-Hodgkin’s lymphoma and colorectal 
carcinoma (Fischer and Schulze-Osthoff, 2005). Despite its tumor specific killing, some tumors 
can survive TRAIL treatment, which presents a major barrier for the development of efficient 
therapies (Kurbanov et al., 2007; Morizot et al., 2010). Resistance to TRAIL has been suggested 
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to be due to increased levels of antiapoptotic proteins such as c-FLIP, Bcl-2, Bcl-xL and 
inhibitors of apoptosis proteins, all of which are regulated by NF-κB.    
 
4.3   Future work 
 In this work, STK38 and STK38L were demonstrated to bind and phosphorylate NF-κB’s 
p65 subunit in vitro. While these two kinases have been studied to a great extent in yeasts, little 
is known about their substrates in mammalian cells (Hergovich et al., 2008). It will therefore be 
important to identify additional substrates of these kinases. Creating knock-in cells that 
expressed active-site STK38/38L mutants that can recognize an ATP analog (using methods 
developed by Shokat and colleagues) (Hindley et al., 2004) and using mass spectrometry to 
identify modified substrates would be one way forward.  
 STK38 and STK38L were shown to modify p65 on several residues, one of which is 
S356. Since this is a novel phospho-acceptor site of p65, in order to study the phosphorylation of 
this site in vivo, it is important that a phospho-specific antibody for p65-S356 is produced. Also, 
modification of p65 at S356 was shown to affect gene transcription of some NF-κB-dependent 
genes including TNF and LTB. There are probably more genes whose expressions are regulated 
by this modification. So it will be interesting to identify these additional genes by creating a 
knock-in cell line carrying a serine to alanine mutation and using gene expression profiling to 
screen for such genes. Also, since NF-κB can be activated by a variety of stimuli, it is likely that 
different genes are affected by p65-S356 phosphorylation in response to different treatments. 
 In the study of how inflammation affects TRAIL-induced cell death behaviors, several 
mechanisms were proposed. Mechanisms resulting in TRAIL resistance involve upregulation of 
FLIP and downregulation of DR4 and DR5. To confirm that FLIP plays an important role, 
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knocking down of this protein is required. As for downregulation of DR4 and DR5, it is obvious 
that this process directly mediates TRAIL resistance. However, what is not obvious is how NF-
κB activation leads to degradation of death receptors. One possible explanation is due to 
expression of a ubiquitin ligase. Work is underway to identify proteins recruited to DR4 and 
DR5 in response to TNFα and IL-1α stimulation that have a ubiquitin ligase function.  
 While activation of the NF-κB pathway by pro-inflammatory cytokines results in 
expression of pro-survival genes, in some case, this pathway can induce expression of pro-death 
genes. Since little is known about the pro-death role of NF-κB, it will be interesting to explore 
this further. While the most likely explanation is due to expression of pro-apoptotic proteins such 
as BID and BAD, it is also possible that regulation at the receptor level can contribute to this 
phenotypic outcome. To examine how homo- versus hetero-trimerization of TRAIL receptors 
influences the cell death response, one can introduce the missing receptor (DR4) into cells that 
express only one type of death receptor, for example DR5. In fact, it has been suggested that 
formation of different types of receptor’s trimers upon TRAIL stimulation can have different 
apoptotic outcomes (Lemke et al., 2010).  
 The NF-κB pathway is known to be involved in activation of many genes. In this work, 
several genes and proteins with the most likely contribution to the overall apoptotic behaviors of 
various cell types were shown. However, this does not rule out the involvement of other genes 
and proteins regulated by NF-κB. A large scale expression profiling of various liver cell lines in 
response to TNF-α and IL-1α using a Luminex bead-based mRNA measurement approach is 
currently underway. This method can profile up to 1000 target gene expression per condition and 
can also process a large number of samples. One hopes that with these types of data, additional 
145 
 
genes and proteins that not only play a role in the apoptosis pathway but also other important 
cellular processes are discovered. 
 
4.4   Closing thoughts  
 The transcription factor NF-κB, more than two and a half decades after its discovery, 
remains an exciting and active area of research. Although NF-κB biology is complex due to 
many layers of its regulation, we are starting to understand more about the role and function of 
this transcription factor in various cellular pathways as well as disease states. While it is no 
doubt that more work needs to be done to uncover new players and mechanisms of gene 
regulation by NF-κB, I hope that this thesis contributes to furthering our knowledge of NF-κB 
and benefiting future research in this field.  
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